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Abstract 
 
Since Cava’s pioneering work on the generation of the very reactive species o-
quinodimethane 1, studies have continued unabated on the modes of preparation, 
physical properties, and synthetic applications of 1 and its derivatives. Several review 
articles published during the past few decades amply bear this out. On the other hand, 
the heteroaromatic analogues 2 have received much less attention, although this 
situation is rapidly changing in recent years. In the background of this development, it 
is surprising that not much systematic work has been done on functional analogues of 
2, e.g. 3 (X = O), which are good candidates for both inter- and intramolecular Diels-
Alder reactions leading to an array of heterocyclic ring systems related to natural and 
non-natural products of biological significance.  
 
 
 
 
  
 
The present research has essentially addressed this issue involving both 4 and 5, 
details of which are described in this thesis entitled “Generation and Trapping of 
Pyridine o-Quinodimethanes and Their Functional Analogues: Synthesis of 
Heterolignans and Conformationally Restricted Analogues of Nicotine.” 
 
The thesis is divided into two chapters, Chapter 1 and Chapter 2. 
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Chapter 1 
This chapter demonstrates that sequential Pummerer-Diels-Alder reaction is 
suited to efficient synthesis of a variety of heterocyclic ring systems including the 
potentially bioactive heterolignans.  Thus, the Pummerer reaction of an o-benzoyl-
substituted pyridylmethyl sulfoxide generates an α-thiocarbocation the interception of 
which by a neighboring keto functionality produces an α-thiosubstituted furo[3,4-
c]pyridine as transient intermediate; the latter undergoes a Diels-Alder cycloaddition 
with an added dienophile. Base-induced ring opening of the cycloadduct followed by 
aromatization gives an isoquinoline derivative that may be looked upon as a 
heterocyclic analogue of 1-arylnaphthalene lignans. The facility of the sequential 
Pummerer-Diels-Alder reaction hinges on the experimental conditions, the best results 
being obtained with heptafluorobutyric anhydride as the triggering agent in toluene 
containing a catalytic amount of p-toluenesulfonic acid. In the absence of a dienophile 
it is possible to isolate and characterize a rather unstable furo[3,4-c]pyridine 
derivative. An intramolecular variant of this protocol is also feasible with use of 
unactivated alkenyl tethers of variable length. The usefulness of the sequential 
Pummerer-Diels-Alder reaction is further demonstrated through the synthesis of a 
heterolignan with a built-in lactone ring via oxidation of the initial [4+2]-cycloadduct 
followed by extrusion of phenyl sulfinate and elaboration of the resulting hydoxylated 
isoquinoline derivative. 
 
Chapter 2 
This chapter deals with the trapping of pyridine o-quinodimethanes generated 
by a formal imine-tautomerisation route.  Thus, reactions of appropriately substituted 
pyridine-derived imines having an ortho methyl/phenylsulfanylmethyl group with 
methyl chloroformate in the presence of Hünig’s base generates transient pyridine o-
quinodimethane intermediates which undergo intramolecular Diels-Alder reaction 
leading to conformationally restricted analogues of nicotine.  That the success of this 
reaction hinges on the presence of a phenylsulfanyl group in the pyridine sidearm has 
been demonstrated as in the earlier investigation reported from this laboratory.  
Recently, conformationally constrained nicotines of the type described in this chapter 
have become targets of intensive investigation in view of their potential use for the 
treatment of various central nervous system (CNS) disorders including Alzheimer’s 
disease, Parkinson’s disease and depression.  
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General Details 
All melting points are uncorrected. Unless otherwise noted, all reactions were 
carried out under an inert atmosphere in flame-dried flasks. Solvents and reagents 
were dried and purified by distillation before use as follows: Tetrahydrofuran (THF), 
benzene, toluene, xylene and diethyl ether (Et2O) from sodium benzophenone ketyl; 
dichloromethane (CH2Cl2), carbon tetrachloride (CCl4) and acetonitrile (CH3CN) 
from P2O5; DMSO and DMF from CaH2; Et3N, pyridine, and diisopropylamine from 
solid KOH; and methanol from Mg. After drying, organic extracts were evaporated 
under reduced pressure and the residue was chromatographed on silica gel (Acme’s, 
particle size 100-200 mesh, SRL 60-120 mesh) using ethyl acetate petroleum ether 
(60-80 °C) mixture as eluent unless specified otherwise. TLC was recorded using 
precoated plate (silica gel GF254 and silica gel G, Merck). 1H-NMR and 13C-NMR 
 were recorded on Bruker AC 200 spectrometers using CDCl3 and mixture of CDCl3 
and CCl4 as solvent and in some cases DMSO-d6. Tetramethylsilane (TMS) was used 
as internal standard (0.0 ppm) in some cases, otherwise CHCl3 (in CDCl3) was used as 
an internal standard (7.25). Chemical shifts are reported in ppm downfield (δ) from 
Me4Si. Coupling constant (Jvalue) were given in Hz. The abbreviation used for 1H- and 
13C-NMR multiplicities follows: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) 
multiplet, (dd) doublet of doublet and (bs) broad singlet. 
 
 
  
 
 
Chapter 1 
 
A Sequential Pummerer-Diels-Alder Route for the 
Generation and Trapping of Furo[3,4-c]pyridines: 
Synthesis of Heterocyclic Analogues of 1-
Arylnaphthalene Lignans 
 
 
 
 
 
 
 
 
 1
1. Introduction 
Isobenzofurans represented by benzo[c]furan (1) have for a long time served as an 
interesting class of reactive intermediates in organic synthesis. As functional analogues of 
o-xylylenes, they take part in both inter- and intramolecular Diels-Alder reactions leading 
 to a variety of polycyclic ring systems including natural 
products of biological significance.1 In contrast, 
heteroanalogues of isobenzofurans have received much less 
attention, although this situation is changing in recent 
years.2,3
O
1
The heteroaromatic isobenzofurans reported to date include furo[3,4-b]furans (2), 
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Figure 1 
thieno[2,3-c]furans (3), furo[3,4-d]oxazoles (4), furo[3,4-d]isooxazoles (5), furo[3,4-
d]thiazoles (6), furo[3,4-b]pyrroles (7), furo[3,4-b]pyridines (8), furo[3,4-c]pyridines (9), 
furo[3,4-d]pyridazines (10), furo[3,4-b]benzofurans (11), furo[3,4-b]indoles (12), 
benzo[4,5]thieno[2,3-c]furans (13), furo[3,4-d]quinoxalines (14) and furo[3,4-
 2
c]cinnolines (15) (Figure 1).3, 4 The parent members of most of the heteroaromatic 
isobenzofurans as shown in Figure 1 are as yet unknown except 9 and 10. However, 
stable derivatives of a number of heteroaromatic isobenzofurans have been made. In this 
chapter a brief overview on the methods of generation of heteroisobenzofurans and their 
applications to the synthesis of natural products and non-natural products, especially 
heterolignans is presented. 
1.1. Generation of heteroisobenzofurans 
Over the years various methods3 have been developed for the generation of 
heteroaromatic isobenzofurans which include flash vacuum pyrolysis5, 6 (eq. 1 & 2), acid 
catalyzed cyclization7 (eq. 3); Grignard reagent promoted cyclization8 (eq. 4); 
Hamaguchi-Ibata reaction9 (eq. 5) and Pummerer reaction10 (eq. 6; see also section 2).  A 
recent addition to this group includes the synthesis of some furo- and thieno[2,3-c]-fused 
heterocycles by reacting non-stabilized and stabilized phosphorous ylides with 2-acetyl-
5-bromothiophene and 2-acetyl-5-methylfuran.11
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1.2. Application of heteroisobenzofurans 
Unlike isobenzofurans, heteroisobenzofurans have not found as much use in the 
synthesis of natural and non-natural products.  However, the limited work published in 
the literature is summarized here. 
Ellipticine 
 4
One of the most interesting applications of heteroisobenzofurans is found in a 
synthesis of the potent anticancer pyridocarbazole alkaloid ellipticine (19).  Thus, Gribble 
et al.7 utilized the cycloaddition of 16 with 3,4-pyridynes which gave a 1:1 mixture of 
two regioisomeric products.  Treatment of the mixture with NaBH4 gave ellipticine 19 
and isoellipticine 20 (Scheme 1).  
Scheme 1 
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Murrayaquinone A 
In 1993, Miki and Hachiken12 synthesized Murrayaquinone A (23) via the 
regioselective cycloaddition reaction of furo[3,4-b]indole 21 with methyl acrylate 
(Scheme 2).  
Scheme 2 
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 5
Thiamarmelerin and thiafugin A 
Sulfur analogues of the furanosesquiterpenes (-)-marmelerin (25) and farfugin A 
(27) have been prepared using intramolecular Diels-Alder reactions of thieno[2,3-
b]furans 24 and 26, respectively (Scheme 3).13
Scheme 3 
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Heterolignans 
Heteroaromatic isobenzofurans have also been used as potential building blocks 
for the synthesis of heterolignans.  In this subsection it is deemed important to discuss the 
chemistry of heterolignans, and not just their synthesis as this is relevant to the work 
presented in this chapter. 
The term heterolignan was first introduced by Ramos et al.14 to define a class of 
compounds developed in a research line directed at the synthesis of new analogues of the 
 6
naturally occurring and biologically significant lignans, the main structural types of 
which is shown in Figure 2.  Heterolignans are those synthetic analogues of lignans  
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Figure 2 
designed as a result of replacing of one or more carbon atoms of the propane moieties 
(C7-C9 and/or C7´-C9´) by heteroatoms and/or replacing one or both benzenic rings (C1-
C6 and/or C1´-C6´) by heteroaromatic systems.  The antitumor agent podophyllotoxin 
(31) and two of its semisynthetic derivatives etoposide (32) and teniposide (33), belong to 
the class of 1-arylnaphthalene lignans 15 (cf. 29 in Figure 2) (Figure 3).  Although these  
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compounds have been used in front-line cancer therapy,16 their therapeutic uses are often 
hindered by problems such as poor bioavailability, myelosuppression, and acquired drug 
resistance.17  With a view to improving clinical efficacy and to overcoming the 
aforementioned problems a vast number of heteroanalogues of podophyllotoxin have 
been made and biological studies carried out.18 Although not comprehensive a list of such 
analogues is given in Figure 4.19 Of these compounds azatoxin 47, a hybrid molecule of  
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ellipticine and etoposide20 has generated a lot of interest in view of its biological 
activity.21 In fact it not only halts tubulin polymerization at variable concentrations but 
also acts as a potent inhibitor of DNA topoisomerase II, another target for anticancer 
agents. It seems that current challenges in heterolignan research centers around 
synthesizing more such hybrid molecules and investigating their biological activities. 
Thus, a synthesis of 48, (Figure 5), a hybrid of antibacterial 4-quinolone and antitumor 
epipodophyllotoxin was developed.22 Indeed it presents significant antiproliferative 
activity to human cancer cell lines (Hela cells and HL 60 leukemia cells) in vitro at 10-5 
M. More recently, Zhao et al.23 synthesized 49, a hybrid of 1-arylnaphthalene lignan with 
isoquinoline alkaloid and its biological evaluation displayed apparent cytotoxicity against 
the A549 cell line with an IC50 value of 5.93 µM. Similarly, bio-assay of 50 shows anti-
inflammatory potency in an adjuvant arthritis (AA) rat model.24 
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      Figure 5 
For synthesis of hetero analogues of 1-arylnaphthalene lignans azaisobenzofurans 
have found use as potential building blocks. The first synthesis of heterolignan 55 
 9
reported by Iwoa et al.25 in 1984, involves the generation of furopyridine 52 as shown in 
Scheme 4. Interception of 52 with dimethyl fumerate led to 53 and 54 which were 
elaborated to heterolignan 55. 
Scheme 4 
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Iwasaki and co-workers26 have reported another route for the synthesis of 1-
arylquinoline lignans.  Thus 56, on treatment with a catalytic amount of trifluroacetic 
acid produced a carbocation which upon intramolecular cyclization and subsequent 
deprotonation generated the furo[3,4-b]pyridine 57. Interception of 57 with 
dimethylacetylenedicarboxylate (DMAD) led to the formation of the desired lignan 
derivative 58 (Scheme 5).  This methodology is also suitable for generation of thieno- as 
well as indole- derived 1-arylnaphthalene lignans (59 and 60) via the intermolecular 
Diels-Alder reaction of the in situ generated thieno[3,4-b]furan and furo[3,4-b]indole, 
respectively (Figure 6).26  
 10
Scheme 5 
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Furthermore, via this protocol a series of 1-pyridylnaphthalene lignans was also made 
and evaluated for their ability to selectively inhibit PDE IV isolated from guinea pig. 
Thus, Iwasaki et al. found that the compound 61 shows potent antispasmogenic activity 
(ED50 = 0.08 mg/kg iv) without producing significant changes in heart rate with the use 
of histamine-induced bronchospasm assay.27  
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      Figure 6 
Kappe and Padwa have made very elegant use of a tandem Pummerer-Diels-Alder 
reaction to access heteroanalogues of 1-arylnaphthalene lignans; however, this work is 
presented in details in Section 2. 
 11
More recently, Sugahara et al.28 also reported the acid catalyzed transformation of 
pyridine substituted hydroxy acetal 62 to 1-pyridylisobenzofuran intermediate 63; the 
latter undergoes rapid Diels–Alder reaction with dimethyl maleate to give 64 and 65 as a 
mixtures (1:1.3) of exo and endo diastereoisomers (Scheme 6). Treatment of 64 and 65 
with BF3.Et2O gave 1-pyridylnaphthalene lignan 66. 
Scheme 6 
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Besides the above mentioned routes, several other approaches have been made 
towards the synthesis of heterolignans.14 However, this is outside the scope of this 
overview and hence no discussion in this regard is warranted. 
 
2. Previous work from this laboratory 
In our laboratory a comprehensive programme was initiated a few years ago to 
develop new and efficient methods for the generation of heterocyclic analogues of 
 12
isobenzofuran, e.g. furo[3,4-c]pyridine and demonstrate their use in the synthesis of 
various heterocyclic ring systems of biological importance.  
 One of the major goals in organic synthesis is to make stable derivatives of the so-
called “reactive intermediates.” For example, the first stable or should we say a ‘bottlable 
carbene’ 67 was reported by Arduengo29 in 1991 (Figure 7). Other examples include the 
crystalline tetramesityldisilene 68, prepared by West30 and the o-xylylene derivative 69,31 
the latter being one of a chance observation rather than a product of rational design. 
Obviously, either electronic or steric or both factors are responsible for the stability of 
these species. In the case of the transient 10-π electron isobenzofuran,32 only a handful of 
stable derivatives are known. The most well-known member of this group is 70 which is 
commercially available and has found wide use as a trapping agent in Diels-Alder 
reactions. Another example is 71.33 In both 70 and 71 the parent isobenzofuran is 
obviously stabilized electronically. 
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      Figure 7 
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In the case of transient furopyridine5a 9 no really stable derivative was known. 
Accordingly, it was of interest to make a stable derivative of this ring system. Padwa et 
al.34 reported in 1997 that introduction of a carboalkoxy group at the 5-position of the 
unstable 2-aminofuran stabilizes the system, i.e. 72. Therefore, it seemed that 
introduction of a push-pull element, namely an amino group and a carboalkoxy group at 
appropriate positions in the parent furopyridine 9 would stabilize the system considerably 
(Figure 8). This turned out to be so in a related dichloro compound, e.g. methyl 
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Figure 8 
 
4,6-dichloro-3-(diethylamino)furo[3,4-c]pyridine-1-carboxylate (73) reported from this 
laboratory.35 Thus, when the substituted diazoacetic ester 74 was exposed to 1 mol% 
Rh2(OAc)4 in CH2Cl2 at room temperature for 1h, the furo[3,4-c]derivative 73 was 
obtained in 50% yield as a bright orange air and light-stable crystalline solid, which 
melted without decomposition at 110-112 ºC (Scheme 7). Compound 73 undergoes 
Scheme 7 
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a facile Diels-Alder cycloaddition with a variety of dienophiles to give polysubstituted 
isoquinoline derivatives via ring opening of initially formed cycloadducts. In each case 
the cycloaddition proceeds with high regioselectivity, with the electron withdrawing 
group located ortho to the amino group (Scheme 8).35b  
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The first example of an intramolecular Diels-Alder reaction involving a furo[3,4-
c]pyridine was also reported from this laboratory.36 For example, exposure of o-
amidodiazocarbonyl precursors 79 to 1 mol% Rh2(OAc)4 in refluxing benzene for 1 h 
gave the bridged anabasine 81 as a yellow crystalline solid formed via intramolecular 
cycloaddition, followed by ring opening and subsequent proton transfer (Scheme 9).36a 
Thus, a novel route to conformationally restricted anabasines, e. g. 81 with potential as 
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therapeutic agents for central nervous system disease and related disorders was 
developed.36b
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Incidentally, when diazoacetic ester 82a was subjected to the Rh(II)-catalyzed 
domino reaction, no intramolecular cycloaddition leading to a bridged nicotine analogue 
84 was obtained, even after heating in refluxing benzene for a prolonged time (Scheme 
10).  However, in this case it was possible to trap the corresponding azaisobenzofuran 
83a with methyl acrylate to furnish cycloadduct 85a.  Unfortunately, even with a built-in 
activated dienophilic moiety as in 82b or with an electron-rich diene partner, e.g. 82c, no 
domino reaction took place to give the corresponding conformationally constrained 
nicotine. A detailed density functional theoretical study (B3LYP/6-31+G**) was 
undertaken to provide insight into the factors that facilitate an intramolecular Diels-Alder 
reaction in the case of 82a.36b 
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 Another piece of work was also undertaken in this laboratory to generate furo[3,4-
c]pyridines based on the Pummerer route originally developed by Padwa et al.37 (cf. eq. 
6).10  At this juncture it is deemed important to review Padwa’s elegant contribution to 
the generation and trapping of isobenzofurans and their hetero analogues. Padwa’s 
strategy for the generation of isobenzofurans via the Pummerer route is shown in Scheme 
11.37a This strategy entails the generation of an α-thiocarbocation and its interception by a 
neighbouring carbonyl group to give thio-substituted isobenzofuran 88 which undergoes 
Scheme 11 
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Diels-alder reaction to give the cycloadduct 89 (Scheme 11). This methodology worked 
very well and Padwa et al. showed the utility of the same by synthesizing a number of 
naturally occurring lignans, such as taiwanin E (94).37a The synthesis of one such target, 
e.g. taiwanin E using acetic anhydride as the triggering agent is shown in Scheme 12.  
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SEt
O
O
O
O
O
O
DMM
Ac2O
CO2Me
CO2Me
OH
O
O
O
O
O
CO2Me
CO2Me
SEt
O
O
O
O
NaBH4
NaIO4
RuCl3
OH
O
O
O
O
O
O
O
CO2Me
CO2Me
SO2Ph
O
O
O
O
p-TsOH
94; taiwanin E
90 91 92
93
It is obvious that Padwa et al. would extend this methodology to the synthesis of 
heteroisobenzofurans.10 However, when they did they ran into a problem.  For example, 
exposure of 95 and 97 to the same reaction conditions gave Diels-Alder adducts 96 and 
98, but in very poor yield (10-20%);10 the main byproducts were identified to be 
compounds of the type 101 (Scheme 14).  These results are surprising considering the 
fact that acetic anhydride is by far the most commonly used reagent and often utilized as 
the solvent at reflux temperature or in combination with other solvents or cocatalysts. 
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Two other Pummerer promoters were also employed by Padwa et al. These include the 
more electrophillic trifluoroacetic anhydride as it allows the reaction to proceed under 
mild conditions in the presence of basic (e.g. pyridine, triethylamine) or Lewis acid 
catalysts (e.g. SnCl4) as well as trimethylsilyltrifluromethanesulfonate (TMSOTf) since 
this reagent permits the reaction to be carried out at temperatures below 0 °C.38  
However, Padwa et al. noted that these conditions were ineffective for forming 
heteroisobenzofurans and in most cases yielded only the classical Pummerer products of  
Scheme 13 
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type 101.10 In order to improve the yield of the desired heterocyclic cycloadducts, Padwa 
et al. introduced a new condition involving the use of catalytic amount of p-
toluenesulfonic acid (p-TsOH) as a cocatalyst with acetic anhydride in refluxing toluene. 
The presence of p-TsOH as a cocatalyst dramatically accelerates the rate of the 
transformation as compared to reactions carried out without p-TsOH.10 The initially 
formed thionium ion 100 (Scheme 14) can either be captured internally by the adjacent 
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carbonyl group to give, after proton loss, the isobenzofuran intermediate 102 or it can 
react in the traditional sense with an external nucleophile (i.e., AcO-) to furnish the 
acetoxy sulfide 101. The presence of p-TsOH effectively drives the reaction in the 
desired direction (100→102) either by preventing the formation of the acetoxy sulfide 
101 or by assisting the ejection of the acetoxy group (101→100), should 101 be formed; 
control experiments indeed supported the latter possibility. Under the new condition, 95 
and 97 yield 96a and 98a in 80% and 90%, respectively (Scheme 13).  The new condition 
was found equally applicable to intramolecular cases (Scheme 15).10 
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Inspired by the pioneering work of Padwa et. al. Sarkar et. al. initiated work on 
generation and trapping of furo[3,4-c]pyridines as depicted in Scheme 16.  
Scheme 16 
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To test the feasibility of this idea a simple sulfoxide precursor 112 was made from 
nitrile 110 by Dr. S. Basak from this laboratory (Scheme 17). Dr. Basak found that when 
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112 was treated with a suitable dienophile e.g. dimethyl maleate under standard 
Pummerer reaction conditions (Ac2O/ p-TsOH, toluene, reflux) developed by Padwa et 
al.10 113 was formed in 44% yield as a white crystalline solid (mp 109-111°C) (Scheme 
18). In this case, the [4+2]-adduct (cf. 109) underwent spontaneous ring cleavage 
followed by dehydration.  
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3. Present work 
The foregoing encouraging results on the generation and trapping of furo[3,4-
c]pyridine prompted us to study the scope and limitations of this work.  Along this line it 
was decided to study tandem Pummerer-Diels-Alder reaction on keto-sulfoxide e.g. 114 
(Scheme 19) where R stands for either aryl or alkenyl groups. While with the former, one 
could get hold of heterolignans e.g. 117, the latter was chosen to test the applicability of 
the Scheme in intramolecular cases leading to tricyclic systems, e.g. 118. Admittedly, the 
proposed heterolignan synthesis is part of a curiosity drive rather than addressing current 
challenges described in Section 1.2.    
Scheme 19 
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4. Results and Discussion 
Our study started from the thio-substituted nicotinaldehyde 111 which on 
treatment with aryl Grignard reagents in THF at -78 °C gave the corresponding alcohol 
(119-121) (Scheme 20) in good yield. The formation of 119-121 was evident from  
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spectral data. For example, the presence of molecular ion peak at m/z 390 ([M+H]+, 
C20H18Cl2NOS) in mass spectrum and appearance of absorption band at 3371 cm-1 due to 
O-H group with disappearance of the absorption band at 1688 cm-1 for aldehyde 111 in 
IR reveals the formation of alcohol 120. In 1H NMR the presence of a singlet at 2.36 for 
CH3C6H4 and doublets at 3.84 and 4.26 with J = 15.3 Hz indicated the AB system for 
CH2SPh protons in 120. The structure of alcohol 120 was further confirmed from 16 line 
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signals in 13C NMR as well as HRMS data. Alcohols 119 and 120 undergo clean 
oxidation to ketones 122 and 123, respectively under Swern oxidation condition. It can be 
mentioned here that alcohol 121 does not undergo oxidation under the same condition; 
rather a mixture of decomposition products (TLC) were formed which were not further 
characterized. The decomposition products might include some chlorinated compounds 
and indeed there is precedent in indole chemistry that chlorination competes over 
oxidation.39 The formation of such products may be explained in terms of the 
involvement of oxygen lone pair towards the formation of unstable intermediate 128a, 
which undergoes rapid decomposition under the reaction conditions (Figure 9).  Later it  
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was found that the alcohol 121 could be converted to the corresponding ketone 124 by 
PCC at room temperature in CH2Cl2 in excellent yield. The structure of 124 was fully 
supported by spectral data. The precursors for the sequential Diels-Alder reaction, 
namely the sulfoxides 125–127 were synthesized from the corresponding sulfides 122–
124 by oxidation with NaIO4 in methanol-water. The structures of sulfoxides 125–127 
were evident from spectral data. For example, in 1H NMR of 126 there is disappearance 
of a singlet at δ 3.90 for two protons of CH2SPh and appearance of doublets at 3.79 and 
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3.92 with J = 12.8 Hz indicating the AB system for CH2SOPh. Presence of molecular ion 
peak at m/z 421 ([M+NH4]+, C20H19Cl2N2OS) in DCI-MS and appearance of absorption 
band at 1668 cm-1 due to carbonyl group, 1327 and 1085 cm-1 due to sulfoxide group in 
IR also support the structure of 126. Finally 13C NMR (16 lines) and HRMS data 
confirmed the structure of 126. The main drawback in the NaIO4-mediated oxidation of 
sulfides 122–124 is long reaction time, i.e. 15 – 20 days are required to obtain sulfoxides 
in acceptable yields. For rapid access to these sulfoxides we subsequently found that 
treatment of keto-sulfides to excess amount of peracetic acid is the method of choice.  For 
example, treatment of 123 with peracetic acid (32 wt %) in ether under refluxing 
condition for 30 minutes gave 70% of the keto-sulfoxide 126 and remaining starting 
material which can be recovered.  
With the keto-sulfoxide 125-127 in hand, we turned our attention to the formation 
of some azalignans via the standard sequential Pummerer-Diels-Alder reaction condition. 
Thus, treatment of keto-sulfoxide 125 with acetic anhydride, p-toluenesulfonic acid in 
presence of dimethyl maleate in refluxing toluene gave the bridged product 132, albeit in 
17% yield only (Scheme 21). The structure of 132 was assigned from 1H NMR showing 
characteristic signals at δ 3.57 as singlet for ester protons (CO2CH3), and doublets at 3.61 
and 4.16 for CH protons with coupling constant 11.2 Hz. Additionally, the presence of 
two quaternary carbon signals at δ 167.6, 168.9 due to two COOCH3, methyl carbon 
signals at δ 51.9 and 52.5 due to COOCH3 along with other 17 lines in 13C NMR 
confirms the structure of 132. The stereochemistry of 132 is tentatively assigned on the 
basis of Alder endo rule. Similarly, when keto-sulfoxides 126 and 127 were subjected to 
the same conditions 133 and 134 were obtained in only 18 and 20% yields, respectively. 
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The formation of the endo-adduct was confirmed from single crystal X-ray structure 
determination of 134. The X-ray work was carried out by Professor H. –K. Fun 
(Malaysia) and the ORTEP diagram is shown in Figure 10. 
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Figure 10. ORTEP diagram of 134 
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The low yield of the cycloadducts 132-134 was due to the formation of Pummerer 
classical products, e.g. acetoxy sulfides of type 135 as major products along with 
miscellaneous other side products, which were not further investigated (Figure 11). For 
example, in the Pummerer reaction of 127, the acetoxy sulfide 136 was isolated as a 
white crystalline compound. Structure of 135 was evident from spectral data. Presence of 
absorption band at 1763 cm-1 due to acetate carbonyl group and 1661 cm-1 due to the 
other carbonyl group in IR reveals the formation of the acetate product. In 1H NMR the  
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     Figure 11 
singlets at δ 1.98 due to the acetate protons and 3.88 due to the methoxy protons support 
the structure of 136.  Furthermore, the presence of OCOCH3 group in 136 was also 
evident from LCMS which shows m/z (relative intensity) at 462 ([M + H]+, 8), 402 ([M –  
OAc]+, 100), 292 ([M – OAc -PhSH]+, 71). The structure of 136 is further confirmed 
from the appearance of a methine carbon signal at δ 77.4 (due to CH(SPh)OAc) along 
with other 17 lines in 13C NMR spectrum. In order to improve the yield of the reaction, 
the keto-sulfoxide 124 was treated with other known Pummerer conditions (e.g. acetic 
anhydride, reflux; acetic anhydride/BF3.Et2O, reflux; trifluoracetic anhydride/ Et3N at 0 
 °C; trifluoroacetic anhydride/p-TsOH) in presence of dimethyl maleate). But surprisingly 
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none of these conditions were suitable for yield improvement. At this stage we wondered 
as to why the yield of cycloadducts in all three cases (Scheme 21) is poorer in 
comparison with the formation of 113 from 112 (Scheme 18). This may be due to the 
steric effect which disfavours the formation of 138 from 137 (Scheme 22) when 
compared with the formation of 139. Therefore, in the presence of stronger nucleophiles 
like acetate ion, 137 leads to compounds of the type 135. This suggests that if very poor 
nucleophiles are present in the medium, species such as 137 will not be trapped and any 
138 formed will undergo elimination of proton to generate the azaisobenzofuran 
intermediate (cf. 115, Scheme 19) leading to the desired cycloadducts.  This prompted us  
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to develop a modified triggering agent in order to achieve acceptable yields of desired 
bridged cycloadducts and heptafluorobutyric anhydride was found to be a better 
triggering agent than acetic anhydride/p-TsOH (Padwa’s condition10). Under this 
modified protocol, keto-sulfoxides 125–127 smoothly gave the bridged cycloadducts 
132–134 with improved yields as shown in Scheme 23. Obviously, this improvement is 
either due to the poorer nucleophilicity of ‘counterion’ (C3F7CO2-) towards Pummerer 
intermediate (cf. 137) generated in the reaction medium, thereby preventing the 
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formation of sulfides of type 135 or, due to better leaving group ability of the same 
‘counterion’ from species, e.g. 135. 
Scheme 23 
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In order to study the stability of the transient intermediates, that is the thio 
substituted furo[3,4-c]pyridines 129-131, the keto-sulfoxide 127 was treated with the 
triggering agent, heptafluorobutyric anhydride/ p-toluenesulfonic acid in the absence of a 
dienophile under reflux condition in toluene. This time we were able to isolate the 
intermediate α-thiosubstituted furo[3,4-c]pyridine 131 as a yellow oil by rapid flash 
chromatography.  We found that 131 is quite unstable and undergoes aerial 
decomposition attended with disappearance of color in a few hours. However, the 
intermediate could be characterized by 1H NMR spectroscopy showing characteristic 
singlets at δ 3.88 and 7.31 for OCH3 group and the pyridine proton, respectively with 
disappearance of doublets at 3.73 and 3.87 for CH2SOPh in 127.  The absence of the 
absorption band at 1687 cm-1 for carbonyl group in IR is also supportive of the structure.   
Furthermore, when 131 was exposed to dimethylmaleate in toluene under reflux, 134 was 
formed in low yield.  It may be noted that azaisobenzofuran 131 also undergoes Diels-
Alder reaction with less reactive dienophiles.   Thus, exposure of 131 to the       
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Pummerer-Diels-Alder reaction protocol in presence of methyl acrylate as dienophile 
gave cycloadducts 140 and 141 as a 4:1 mixture as evident from the relative intensity of 
the COOMe signals in 1H NMR (Scheme 24). It may be mentioned here that the major 
product 140 was isolated as white crystals by crystallization of the mixture from 5% ethyl 
acetate:petroleum ether. 
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The formation of the bridged adduct was evident from spectral data. The 1H NMR 
spectrum of 140 shows a typical ABC pattern of splitting at δ 2.12 (dd, 1H, J1 = 12.2 Hz, 
J2 = 4.2 Hz), 2.58 (dd, 1H, J1 = 12.2 Hz, J2 = 10.2 Hz) for CH2 protons and 3.91 (dd, 1H, 
J1 = 10.2 Hz, J2 = 4.2 Hz) for CHCO2Me. In 13C NMR the appearance of methine carbon 
signal at δ 47.7 due to CHCO2Me and methyl carbon signal at 52.4 due to CHCO2Me 
along with other 17 signals confirm the formation of cycloadduct 140.  The 
stereochemical assignment for 140 was confirmed from single crystal X-ray 
crystallography.40 The ORTEP diagram and crystal packing of 140 is presented in 
Figures 12 and 13, respectively. The structure of minor product is tentatively assigned as 
141 (Scheme 24). It is appropriate to mention here that Padwa et al.10 reported that 
treatment of ethyl thio-substituted thieno[2,3-c]furan 142 with methyl acrylate in 
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presence of Sc(OTf)3 gave the only regio isomer 143 which undergoes instantaneous 
dehydration to give the fully aromatized product 144 (Scheme 25). They mentioned that 
the ethylthio group plays an important role in terms of influencing the regiochemistry of 
Diels-Alder reaction. It may be noted that in the work of Friedrichsen et al.41 the Diels-
Alder reaction of 4,6-diphenyl thieno[2,3-c]furan 145 with methyl acrylate followed by 
dehydration produce 1:1 regioisomeric cycloadducts 146 and 147.  Padwa et al. reported 
that the formation of adduct 144 as a single regioisomer is consistent with FMO theory. 
The most favorable interaction is between the HOMO of the thieno[2,3-c]furan and 
LUMO of methyl acrylate. The atomic coefficient at the ethylthio-substituted position in 
furan ring is larger than at the phenyl position in the HOMO and this nicely 
accommodates the high regioselectivity encountered.  
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Figure 12. ORTEP diagram of 140 
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Figure 13. Crystal packing diagram of 140 
  
 In our case the regio- and stereoselectivity in the cycloaddition of 131 with 
methyl acrylate may also be rationalized by FMO theory.42 The orbital co-efficients as 
well as energy difference between the HOMO of 131 and LUMO of methyl acrylate 
(MA) were determined by restricted Hartree-Fock ab-initio calculations using GAMESS 
quantum chemistry package.43 The calculations were carried out using two basis sets with 
Gaussian basis set i.e. Slater-type orbitals (STO 3-21G* and STO 6-31G**) for 
comparison.  In fact, Firoj Jaipuri (USA) did the calculation with GAMESS HF/3-21 G* 
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initially and later the results were verified using the other basis sets by Sajeev 
Yasoodharan (Technion, Israel Institute of Technology, Israel) (Table 1). It has been 
concluded that the atomic coefficient of the phenylthio-substituted carbon in the 
heteroisobenzofuran ring is larger than the anisyl substituted carbon in the HOMO of 
131.  This matches with the bigger atomic coefficient of CH2 carbon and smaller CH 
carbon of methyl acrylate (MA) respectively in LUMO to accommodate the 
regioselective product 140 from the Diels-Alder reaction.  
 
Table 1 
GAMESS/ 
Basis sets 
Energy 
Difference : 
LUMO of 
MA and 
HOMO of 
131 
Orbital co-
efficient of 
SPh 
substituted 
C of 131 
Orbital co-
efficient of 
anisyl 
substituted 
C of 131 
Orbital co-
efficient of 
CH2 
(terminal) C 
of MA 
Orbital 
co-
efficient 
of CO2Me 
substituted 
CH of MA
HF/ 3-21G* 4.8 ev 0.314 0.23 0.63 0.464 
HF/6-
31G** 
10.13 ev 0.481 0.420 0.930 0.688 
 
The Pummerer-based route for the generation and trapping of α-thiosubstituted 
furo[3,4-c]pyridines can also be extended to intramolecular cases. The precursors for 
intramolecular Diels-Alder reaction, that is tethered sulfoxides 153 and 154 were 
prepared in a similar fashion as described in Scheme 20. Treatment of the thio-substituted 
nicotinaldehyde 111 with alkenyl Grignard reagents at -78 °C in THF gave the 
corresponding alcohols 148 and 149, respectively in 32-36% yield (Scheme 26), which 
were characterized by 1H as well as 13 C NMR. Here, the poor yield of the alcohol is due 
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to the formation of (2,6-dichloro-4-((phenylthio)methyl)pyridine-3-yl)methanol (150) as 
a byproduct. The structure of 150 is confirmed from its spectral data. Presence of  
Scheme 26 
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molecular ion peak at m/z 300 ([M+H]+, C13H12Cl2NOS) in the mass spectrum revealed 
the formation of 150. In 1H NMR two singlets at δ 4.12 and 4.76 for two methylene 
protons and another singlet at 6.89 for the pyridine proton established the structure of 
alcohol 150, which was further confirmed by 11 lines in the 13C NMR spectrum.  The 
yield of 148/149 could have been improved if the alkenyl Grignard reagents were 
replaced by the corresponding lithiated reagents; however, this was not done. The 
alcohols 148 and 149 undergo clean oxidation to the corresponding ketones 151 and 152 
by PCC in CH2Cl2.  The formation of ketones 151 and 152 was evident from spectral 
data. For example, the presence of molecular ion peak at m/z 383 ([M+NH4]+, 
C18H21Cl2N2OS) in the mass spectrum and presence of absorption band at 1707 cm-1 in 
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IR spectra reveals the formation of ketone 151. In 13C NMR the disappearance of the 
methine carbon signal (CHOH) at δ 71.1 and appearance of quaternary carbon signal at 
202.7 for CO established the formation of ketone 151. The keto-sulfides on treatment 
with NaIO4 for 3-4 days in methanol-water gave the keto-sulfoxides 153 and 154. 
Formation of keto-sulfoxides 153 and 154 was evident from spectral data. Presence of 
absorption band at 1702 cm-1 for carbonyl group in IR spectra and the appearance of 
doublets at δ 3.71 and 4.12 ( J = 12.9 Hz, AB system) for CH2SOPh in 1H NMR proves 
the formation of sulfoxide 153. 
Subjection of 153 and 154 to the modified Pummerer conditions 
(heptafluorobutyric anhydride/p-TsOH) led to polycyclic ring systems 159 and 160, 
respectively in one pot with good yields (Scheme 27). Structures of 159 and 160 were 
fully established by spectral data. For example, in 1H NMR of 159, the presence of clean 
triplets at δ 3.03 (J = 7.7 Hz) and 3.74 (J = 7.5 Hz) and disappearance of the multiplets 
for terminal double bond at 5.05 and 5.50 along with appearance of two singlets at 7.78 
and 8.20 for two aromatic protons provides evidence for the formation of tricyclic 
compound 159. Furthermore, in 13C NMR disappearance of the quaternary carbon signal 
(CO) of 153 at δ 203.3 and presence of only three triplet carbon signals at 24.3, 33.3 and 
36.4 for three methylene carbons along with other 13 lines proves the structure. The need 
for our new triggering agent for initiating the Pummerer reaction is best exemplified in 
these intramolecular series.  For example, when keto-sulfoxide 153 was subjected to the 
other Pummerer condition, i.e. refluxing with Ac2O in presence of p-TsOH10 no trace of 
product resulting from an intramolecular Diels-Alder reaction could be detected in the 
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Scheme 27 
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crude reaction mixture by TLC; rather the acetoxy product 161 was formed in 63% yield 
(Scheme 28).  The structure of 161 is settled on the basis of spectral data, especially after 
comparing the spectral data with our previous acetoxy byproduct i.e. 136 as well as 151  
Scheme 28 
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(Table 2).  In IR the presence of absorption bands at 1756 cm-1 is due to the acetoxy 
carbonyl group and the one at 1701 cm-1 due to the other carbonyl group. The molecular 
composition of 161 was evident from HRMS data (m/z 424.0542, [M+H]+, 
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C20H20Cl2NO3S).  The 1H- NMR of 161 shows characteristic singlets at δ 2.12 and 6.85 
for (OCOCH3) and CH(SPh)OAc, respectively  with disappearance of the doublets at  
3.71 and  4.12 for CH2(SOPh) in 153. The presence of the signals for the olefinic protons 
as well as for the aliphatic CH2 groups proves the presence of a dangling aliphatic chain 
with a terminal double bond. In 13C NMR, the presence of quaternary carbon signals at δ 
202.3 and 168.9 is due to COCH2CH2 and OCOCH3 respectively; note that the 
disappearance of the signal for CH2(SOPh) at 59.0 and appearance of methine carbon 
signal for CH(OCOCH3) at 76.5 and methyl carbon signal CH(OCOCH3) at 20.9 rule out 
the possibility of any other structure such as the cyclic product 162.  Furthermore, if 162 
was the product, one would expect it to form as a mixture of two diastereomers, not one; 
the 13C NMR of 161 shows that it is a single compound.  One question that may be raised 
at this point is why this molecule i.e., 161 does not fragment in refluxing toluene. This 
may be due to the poor leaving group ability of the acetoxy group. Besides, such 
byproducts (cf. 101) have been reported by Padwa10 under similar conditions.  
Incidentally, 161 is a robust molecule and it does not decompose to the corresponding 
aldehyde.  The high-yielding intramolecular [4+2]-cycloaddition reaction of 155 and 156 
is obviously related to entropic factors which place the tethered double bond in close 
proximity to the diene system. 
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Table 2 
Compounds IR  1H NMR 13C NMR 
N
Cl
Cl
OAc
SPh
O
OMe
136  
1763 cm-1 for 
OCOCH3
1661 cm-1 for 
COAr 
 
7.16 ppm 
(CH(SPh)OAc) 
189.9 ppm 
(COAr) 
168.3 ppm 
(OCOCH3) 
77.4 ppm 
(CH(SPh)OAc) 
O
N
Cl
Cl
SPh
OAc
161  
1756 cm-1 for 
OCOCH3
1701 cm-1 for 
COCH2- 
 
6.85 ppm 
(CH(SPh)OAc) 
202.3 ppm 
(COCH2-) 
168.7 ppm 
(OCOCH3) 
76.5 ppm 
(CH(SPh)OAc) 
O
N
Cl
Cl
SPh
151  
1707 cm-1 for 
COCH2- 
 
 202.7 ppm 
(COCH2-) 
 
 
 
Appropriately functionalized polycyclic aromatic compounds have anti-tumor 
activity by virtue of their ability to intercalate between adjacent heterocyclic bases of 
DNA.44 By contrast, non-planar precursors to such molecules are likely to exhibit low 
affinity for DNA. Chemical insight allowed us to consider azaisobenzofuran-derived 
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Diels-Alder adducts 132-134 as low cytotoxicity precursors, ‘prodrugs,’ of intercalating 
agents. The activation of such adducts selectively at a tumour site might form the basis of 
anti-cancer chemotherapies with reduced side effects. Prodrug activation strategies have 
been pursued with increasing vigour in recent years.45 Since thiol groups can be released 
from appropriately substituted precursors at tumors, namely by bioreduction46 or by 
antibody-directed enzyme catalysis47 azaisobenzofuran Diels-Alder adducts e.g. 132-134 
with bridgehead sulfide groups maybe looked upon as potential antitumour prodrugs 
where cleavage of a sulfide linkage can lead to aromatization of the oxanorbornyl ring 
system 48 (Figure 14). 
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Figure 14 
 Chemically, we have been able to accomplish aromatization of 132-134 with 
DBU in refluxing toluene to give 163-165 in 45-55% yields (Scheme 29).  Structures of 
these products were established from spectral data. For example, 1H NMR spectrum of 
163 shows appearance of signals at δ 3.43 (s, 3H, CO2CH3), 3.88 (s, 3H, CO2CH3), 7.15-
7.32 (m, 6H, aromatic protons), 7.35-7.48 (m, 4H, aromatic protons), 8.37 (s, 1H, 
pyridine proton) and disappearance of signals at 3.61 (d, 1H, J = 11.2 Hz, CH), 4.16 (d, 
1H, J = 11.2 Hz, CH) corresponding to starting material thus indicating that is a fully 
aromatized compound. In 13C NMR, the disappearance of methine carbon signals of 132 
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at δ 52.6 and 53.6 accounts for the structure of 163.  Structure of 163 is further confirmed 
from X-ray single crystal structure determination.49 Figures 15 and 16 represent the 
ORTEP and crystal packing perspective view of 163.  Incidentally, initial attempts for the 
ring opening of 132-134 using a variety of other reagents, e.g. MeOH/HCl, p-TsOH in 
refluxing toluene and CF3COOH were ineffective; in each case the starting material was 
recovered intact.  The synthesis of these compounds, e.g., 165 can also be conducted in 
one pot by exposing sulfoxide 127 to the modified Pummerer conditions and then adding 
DBU to the reaction mixture. 
 
Scheme 29 
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    Figure 15. ORTEP prospective view of 163 
 
 
 
 
 
 
 
 
 
 
 
    
Figure 16. Crystal packing diagram of 163                                                          
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Furthermore, the usefulness of the sequential Pummerer-Diels-Alder reaction 
was demonstrated through the synthesis of a heterolignan with a built-in lactone ring via 
oxidation of the initial [4+2]-cycloadduct followed by extrusion of phenyl sulfinate and 
elaboration of the resulting hydoxylated isoquinoline derivative (Scheme 30 and 31). 
Thus, the phenylsulfanyl group present in 133 was oxidized37a using NaIO4 in presence 
of a catalytic amount of RuCl3 to give sulfone 166 in very good yield within 2h. The 
presence of the molecular ion peak at m/z 579 ([M + NH4]+, C26H24Cl2N2O6S) in DCI-
MS and presence of sulfonyl absorption band at 1164 cm-1 in IR spectrum suggested the 
formation of sulfone 166. The 1H and 13C NMR of 166 also agreed with the structure. 
Ring opening followed by extrusion of phenylsulfinate was done by exposure of 166 to 
DBU in refluxing toluene to give the hydroxy isoquinoline derivative 167 (Scheme 30). 
The characteristic signals for 167 in 1H NMR (200 MHz, CDCl3) are δ 8.31 (s, 1H, 
pyridine proton), 12.42 (s, 1H, phenolic OH) and disappearance of signals from 166 at δ 
4.21 (d, 1H, J = 11.2 Hz), 4.29 (d, 1H, J = 11.2 Hz). The presence of the molecular ion 
peak at m/z 437 ([M + NH4]+, C20H19Cl2N2O5) in DCI-MS and m/z 420.0410 ([M+H]+, 
C20H16Cl2NO5) in HRMS confirms the elimination of SO2Ph group and formation of the 
isoquinol derivative 167.  
With the isoquinol derivative 167 in hand we turned our attention to the synthesis 
of lignanolides by converting the diesters to corresponding lactone e.g. 117. We found 
from the literature that the analogous naphthol derivatives e.g. 93 can be easily reduced to 
lactones by sodium borohydride in methanol,50, 37a although reduction of esters by sodium 
borohydride is unusual. In this case the initial complexion of the reagent with the 
adjacent phenol group helps selective reduction of the desired ester group. Accordingly, 
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sodium borohydride should selectively reduce the diester 167 to the desired lignanolide 
169.50, 37a Unfortunately, we failed to obtain any lactone from the sodium borohydride 
reduction. Rather we got a mixture of products which were not characterized further. We  
Scheme 30 
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overcame this problem by prior methylation of the hydroxy group and DIBAL-H 
reduction of the resulting methyl ether 168 to give the heterolignan 169 directly 
(Scheme 31).  The presence of molecular ion peak at m/z 374 ([M+H]+, C19H14Cl2NO3 ) 
in the mass spectrum and carbonyl absorption band at 1779 cm-1 due to the γ-lactone in 
IR spectrum revealed the formation of 169. In 1H NMR, the disappearance of methyl 
ester signals at δ 3.34, 3.93 (corresponding to starting material 168) and the appearance 
of characteristic singlets at 2.45 and 4.19 accounted for the tolyl CH3  and OMe group 
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of 169, respectively; also, the singlets at δ 5.59 for -CH2OCO group and δ 8.14 for one 
proton attached to the pyridine ring explained the structure. Additionally, in 13C NMR 
Scheme 31 
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the disappearance of the two methyl carbon signals at δ 52.2, 53.0 (due to two CO2CH3 
of 168) and one quaternary carbon signal at 165.4 (due to one of the COO of 168) and 
appearance of methylene carbon signal (CH2OCO) at  65.8 confirms the reduction of 
diester to lactone 169. Other respective signals in 13C NMR at 21.5 (q), 59.9 (q), 114.8 
(d), 124.5 (s), 125.7 (s), 128.5 (d), 129.0 (s), 129.3 (d), 131.7 (s), 137.0 (s), 137.7 (s), 
138.2 (s), 145.3 (s), 147.8 (s), 152.5 (s), 167.3 (s) fully support the number of carbons 
and their nature. 
The position of the lactone carbonyl in 169 was determined by NOE experiments, 
which show a significant enhancement of the OMe signal at δ 4.19 upon irradiation of the 
adjacent CH2 singlet at δ 5.59. Furthermore, on irradiation of OMe signal at δ 4.19 shows 
an enhancement at δ 5.59 (CH2OCO signal), as well as at δ 8.14 due to adjacent pyridine 
proton. The selectivity in the ester reduction stems from the fact that the tolyl group 
which is orthogonal to the plane of the isoquinoline ring effectively shields the adjacent 
carbomethoxy group.  
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5. Conclusion 
 
In conclusion, we have demonstrated that the sequential Pummerer-Diels-Alder 
reaction sequence is suited to efficient synthesis of a variety of heterocyclic ring systems 
including some 1-arylnaphthalene lignans. The key intermediates in this cascade process 
are α-thiosubstituted furo[3,4-c]pyridines, which in some cases can be isolated and 
independently reacted with a suitable dienophile to give [4+2]-cycloadducts. However, 
we found it to be most convenient to carry out these reactions in an all tandem fashion. In 
addition intramolecular trapping of the in-situ generated furo[3,4-c]pyridine is an 
efficient route for the rapid access to annulated isoquinoline derivatives. Our results 
clearly indicate that this methodology provides rapid entry into heteroaromatic o-
quinodimethanes.  
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6. Experimental 
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2,6-Dichloro-4-[(phenylthio)methyl]nicotinonitrile (110). 
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(a) A mixture containing cyanoacetamide (5.06 g, 60.21 mmol) and ethyl 4-
(phenylthio)acetoacetate51 (14.33 g, 60.21 mmol) in 50 mL of methanol was warmed to 
attain solution and potassium hydroxide (4.14 g, 73.82 mmol) dissolved in 20 mL of 
methanol was added dropwise with stirring. The mixture was heated reflux; after 2 h a 
brown precipitate formed and heating was continued for an additional 5 h. Then the 
reaction mixture was cooled and 2,6-dihydroxy-4-[(phenylthio)methyl]nicotinonitrile 
monopotassium salt so formed was separated by filtration, dissolved in warm water, 
cooled, and acidified with concentrated hydrochloric acid. The product was separated by 
filtration, washed with cold methanol, dried in air, and finally further dried at 120-130 °C 
in vacuo for 5h to give 8.4 g (55%) of 2,6-dihydroxy-4-[(phenylthio) 
methyl]nicotinonitrile as off-white solid: chars at 268 °C, mp 275-278 °C. 
 
IR (KBr) 3100, 2221 cm-1. 
 
1H NMR (200 MHz, CDCl3:DMSO-d6) δ 3.98 (s, 2H), 5.68 (s, 2H), 7.10-7.43 (m, 6H). 
13C NMR (50 MHz, CDCl3, DMSO-d6) δ 36.1 (t), 89.2 (s), 92.1 (d), 116.0 (s), 126.7 (d), 
128.8 (d), 129.7 (d), 134.1 (s), 159.0 (s), 161.3 (s), 161.8 (s). 
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(b) A mixture containing 2,6-dihydroxy-4-[(phenylthio) methyl]nicotinonitrile (4 g, 15.5 
mmol) and POCl3 (5.8 mL, 62.0 mmol) was heated in a sealed tube at 150 °C for 9 h. It 
was then cooled to room temperature and transferred into 100 mL of ice cold water. The 
mixture was filtered with repeated washings with water. The residue was dissolved in hot 
methanol, heated for 10 min with activated charcoal, filtered, and concentrated. The 
resulting brown oil was purified by chromatography (EtOAc:petroleum ether 1:99) to 
give 2.45 g (54%) of 110 as a yellow solid. A purer sample was obtained by 
recrystallization from petroleum ether to give colorless needles: mp 117 °C (mp 118-119 
°C, reported by Dr. S. Basak from this laboratory). 
 
IR (KBr) 2231, 1567, 1530, 1336 cm-1. 
 
1H NMR (200 MHz, CDCl3) δ 4.12 (s, 2H), 7.13 (s, 1H), 7.32 (br s, 5H). 
13C NMR (50 MHz, CDCl3) 37.5 (t), 109.2 (s), 112.6 (s), 123.1 (d), 128.6 (d), 129.3 (d), 
131.9 (s), 132.5 (d), 152.5 (s), 153.6 (s), 156.3 (s). 
 
2,6-Dichloro-4-[(phenylthio)methyl]nicotinaldehyde (111) 
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To a stirred solution of 110 (4 g, 13.56 mmol) in 60 mL of CH2Cl2 cooled to -78 
oC was added 15 mL of DIBAL-H (1.0 M solution in toluene) dropwise over a period of 
1h. The resulting mixture was allowed to attain room temperature. After 2 h of stirring at 
room temperature the solution was quenched with saturated aqueous NH4Cl at 0 oC, 
stirred for another 1 h at that temperature and then acidified with 3 N HCl. The organic 
layer was separated and the aqueous layer was extracted with CH2Cl2 (2 × 10 mL). The 
combined organic fractions were washed with saturated aqueous NaHCO3, brine, dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by chromatography (EtOAc: petroleum ether 1:99) to give 2.7 g (67%) of the 
title compound 111 as white crystalline solid: mp. 59-60 °C (mp. 61-62 °C, reported by 
Dr. S. Basak from this laboratory). 
 
IR (KBr) 1688, 1565, 1526, 1317 cm-1. 
 
1H NMR (200 MHz CDCl3:CCl4 7:3) δ 4.36 (s, 2H), 7.00 (s, 1H), 7.28 (br s, 5H), 10.42 
(s, 1H). 
13C NMR (50 MHz, CDCl3): δ 36.2 (t), 124.9 (s), 125.0 (d), 128.0 (d), 129.1 (d), 132.2 
(d), 133.3 (s), 153.4 (s), 154.2 (s), 154.4 (s), 190.2 (d). 
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{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}(4-methylphenyl)methanol (120). 
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To a stirred solution of aldehyde 111 (1 g, 3.5 mmol) in 20 mL of dry THF was 
added dropwise a tolylmagnesium bromide solution (16.8 mL, 0.4 M) [prepared from p-
bromotoluene (1.23 mL, 10 mmol) and Mg (480 mg, 20 mmol) in 24 mL of THF] over a 
period of 10 min at -78 °C. During addition a blood red color was formed. After 1h of 
stirring the mixture was slowly warmed to 0 °C and then quenched with saturated 
aqueous NH4Cl. The organic layer was separated and the aqueous layer was extracted 
with diethyl ether (3 × 10 mL). The combined organic layer was dried over anhydrous 
Na2SO4, concentrated under reduced pressure, and purified by chromatography 
(EtOAc:petroleum ether 10:90) giving 950 mg (73%) of 120 as a white crystalline solid: 
mp 129 -131 °C. 
 
IR (KBr) 3371, 1575, 1524, 1104 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 2.36 (s, 3H), 3.46 (s, 1H), 3.84 (d, 1H, JAB = 
15.3 Hz), 4.26 (d, 1H, JAB = 15.3 Hz), 6.57 (br s, 1H), 6.82-7.41 (m, 10H). 
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13C NMR (50 MHz, CDCl3: CCl4 7:3) δ 21.1 (q), 35.4 (t), 70.9 (d), 125.0 (d), 125.2 (d), 
127.0 (d), 129.0 (d), 129.3 (d), 130.1 (d), 134.3 (s), 134.4 (s), 137.2 (s), 137.6 (s), 149.5 
(s), 149.8 (s), 152.9 (s). 
 
FAB MS m/z (rel intensity) 390 ([M + H]+, 100), 372 ([M - H2O]H+, 26), 279 (31), 264 
(42), 227 (10), 219 (5), 188 (4), 120 (10). 
HRMS (FAB) calcd for C20H18Cl2NOS (M+H)+ m/z 390.0486, found 390.0486. 
 
Anal. Calcd for C20H17Cl2NOS: C, 61.56; H, 4.38; N, 3.58. Found: C, 61.34; H, 4.19; N, 
3.85. 
{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}(phenyl)methanol (119) 
 
N
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Cl
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was prepared by a similar method starting from aldehyde 111 (820 mg, 2.75 mmol) and 
bromobenzene in 77% yield as a white crystalline solid: mp 146-148 °C. 
 
IR (KBr) 3506, 1605, 1571, 1326, 1066 cm-1. 
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1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3.2 (br s, 1H), 3.80 (d, 1H, JAB = 15.2 Hz), 4.23 
(d, 1H, JAB = 15.2 Hz), 6.62 (s, 1H), 6.98-7.45 (m, 11H). 
13C NMR (50 MHz, CDCl3) δ 35.5 (t), 70.9 (d), 125.0 (d), 125.1 (d), 127.1 (d), 127.5 (d), 
128.5 (d), 129.0 (d), 130.3 (d), 133.9 (s), 134.0 (s), 140.4 (s), 149.5 (s), 149.9 (s), 152.6 
(s). 
 
Anal. Calcd for C19H15Cl2NOS: C, 60.66, H, 4.01; N, 3.72. Found: C, 60.61; H, 3.91; N, 
3.85. 
{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}(4- methoxyphenyl)methanol 
(121)  
N
Cl
Cl
SPh
OH
OMe
121
 
 
 
 
 
 
was prepared by a similar method starting from aldehyde 111 (450 mg, 1.51 mmol) and 
p-bromoanisol in 69% yield as a white crystalline solid: mp 116-118 °C. 
 
IR (KBr) 3351, 1569, 1525, 1098 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3.50 (br s, 1H), 3.78 (s, 3H), 3.86 (d, 1H, JAB = 
15.3 Hz), 4.27 (d, 1H, JAB = 15.2 Hz), 6.56 (br s, 1H), 6.72-7.35 (m, 10H). 
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13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 35.5 (t), 55.3 (q), 70.8 (d), 114.1 (d), 125.1 (d), 
126.6 (d), 127.2 (d), 129.1 (d), 130.3 (d), 132.6 (s), 134.3 (s), 149.5 (s), 149.8 (s), 152.9 
(s), 159.1 (s). 
 
Anal. Calcd. for C20H17Cl2NO2S: C, 59.13; H, 4.21; N, 3.44. Found: C, 59.41; H, 4.31; N, 
3.19. 
1-{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}- hex-5-en-1-ol (148)  
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was prepared by a similar method starting from aldehyde 111 (400 mg, 1.34 mmol) and 
5-bromo-1-pentene in 36% yield. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 1.31- 2.18 (m, 6H), 4.18 (d, 1H, JAB = 13.3 Hz), 
4.43 (d, 1H, JAB = 13.3 Hz), 4.89-5.08 (m, 2H), 5.27-5.37 (m, 1H), 5.62-5.91 (m, 1H), 
7.01 (s, 1H), 7.19-7.40 (m, 5H). 
13C NMR (50 MHz, CDCl3:CCl4 70:30) δ 25.4 (t), 33.3 (t), 35.8 (t), 36.4 (t), 71.1 (d), 
115.1 (t), 125.4 (d), 127.7 (d), 129.2 (d), 131.7 (d), 134.4 (s), 134.5 (s), 138.0 (d), 148.3 
(s), 148.9 (s), 151.7 (s).  
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Anal. Calcd for C18H19Cl2NOS: C, 58.71; H, 5.19; N, 3.80. Found: C, 58.93; H, 5.31; N, 
3.49. 
2, 6-Dichloro-4-((phenylthio)methyl)pyridine-3-yl)methanol (150) was formed in the 
above reaction as an oil in 40% yield. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 4. 12 (s, 2H), 4.80 (s, 2H), 6.89 (s, 1H), 7.28 (bs, 
5H). 
13C NMR (50 MHz, CDCl3) δ 36.6, 58.2, 124.3, 128.2, 129.3, 131.1, 132.0, 133.0, 149.3, 
151.1, 151.9. 
 
HRMS (CI) calcd for C13H12Cl2NOS (M)+ m/z 300.0017, found 300.0009. 
1-{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}- hept-6-en-1-ol (149)  
 
N
Cl
Cl
SPh
OH
149
 
 
 
 
was prepared by a similar method starting from aldehyde 111 (440 mg, 1.47 mmol) and 
6-bromo-1-hexene in 32% yield as a yellow oil. 
 
IR (CHCl3) 3308, 1568, 1533, 1307 cm-1. 
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1H NMR (200 MHz, CDCl3:CCl4 70:30) δ 1.28-2.15 (m, 8H), 2.47 (br s, 1H), 4.27 (d, 
1H, JAB = 13.4 Hz), 4.44 (d, 1H, JAB = 13.4 Hz), 4.90-5.05 (m, 2H), 5.21-5.45 (m, 1H), 
5.65- 5.85 (m, 1H), 7.04 (s, 1H), 7.27-7.40 (m, 5H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 25.5 (t), 28.4 (t), 33.5 (t), 36.1 (t), 36.4 (t), 71.1 
(d), 114.5 (t), 125.3 (d), 127.7 (d), 128.9 (d), 131.6 (d), 134.4 (s), 134.6 (s), 138.5 (d), 
148.2 (s), 148.9 (s), 151.7 (s). 
{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}- (phenyl)methanone (122).  
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To a stirred solution of oxalyl chloride (0.278 mL, 3.13 mmol) in 10 mL of 
CH2Cl2 cooled at -60 °C was added DMSO (0.453 mL, 6.39 mmol) in 5 mL of CH2Cl2 
dropwise via dropping funnel in 15 min under argon atmosphere. The mixture was stirred 
for 30 min followed by addition of 119 (800 mg, 2.13 mmol) in 10 mL of CH2Cl2 over a 
period of 10 min. After 30 min of stirring Et3N (1.5 mL, 10.65 mmol) was added and the 
reaction mixture was allowed to attain room temperature and stirred for 1 h. Then 100 
mL of cold H2O was added to the mixture. The organic layer was separated and washed 
with 1% HCl and brine. Finally the organic fraction was concentrated in vacuo and 
purified by chromatography (EtOAc:petroleum ether 5:95) to give 670 mg of 122 in 84% 
yield. 
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IR (KBr) 1666, 1602, 1555, 1332 cm-1. 
 
1H NMR (200 MHz CDCl3:CCl4 7:3) δ 3.90 (s, 2H), 7.00-7.85 (m, 11H). 
13C NMR (50 MHz CDCl3:CCl4 7:3) δ 35.7 (t), 123.7 (d), 127.6 (d), 128.9 (d), 129.2 (d), 
129.6 (d), 130.9 (d), 132.7 (s), 133.5 (s), 134.5 (d), 135.8 (s), 146.7 (s), 150.8 (s), 151.1 
(s), 192.5 (s). 
{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}(4-methylphenyl)methanone (123) 
 
Me
Cl
Cl
SPh
ONN
Cl
Cl
SPh
OH
Me
PCC
123120
 
 
 
 
 
 
To a stirred solution of 120 (2 g, 5.12 mmol) in 20 mL of dry CH2Cl2 was added 
PCC (1.7 g, 7.7 mmol) at room temperature. After 1.5 h of stirring the solution was 
filtered over a short Celite pad. The yellow solution was then concentrated under reduced 
pressure and purified by chromatography (EtOAc:petroleum ether 5:95) to give 1.55 g 
(78%) of 123 as a white solid: mp 105-107 °C. 
 
IR (KBr) 1658, 1602, 1565, 1325 cm-1. 
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1H NMR (200 MHz, CDCl3: CCl4 7:3) δ 2.42 (s, 3H), 3.90 (s, 2H), 7.05-7.35 (m, 8H), 
7.64 (d, 2H, J = 8.0 Hz). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 21.9 (q), 35.6 (t), 123.6 (d), 127.5 (d), 129.1 (d), 
129.7 (d), 129.8 (d), 130.8 (d), 133.0 (s), 133.4 (s), 133.6 (s), 145.7 (s), 146.7 (s), 150.6 
(s), 150.9 (s), 192.0 (s). 
 
Anal. Calcd for C20H15Cl2NOS: C, 61.87; H, 3.89; N, 3.60. Found: C, 62.09; H, 3.97; N, 
3.83.  
{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}(4-methoxyphenyl)methano-ne 
(124) 
N
Cl
SPh
OH
OMe
Cl
OMe
N
Cl
Cl
SPh
O
PCC
121 124
 
 
 
 
 
 
was obtained by the PCC oxidation of alcohol 121 (400 mg, 0.98 mmol) in 96% yield as 
a yellow oil. 
 
IR (KBr) 1660, 1595, 1564, 1343 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3.88 (s, 3H), 3.90 (s, 2H), 6.90 (d, 2H, J = 9.1 
Hz), 7.12-7.28 (m, 6H), 7.70 (d, 2H, J = 8.6 Hz). 
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13C NMR (50 MHz, CDCl3:CCl4 70:30) δ 35.6 (t), 55.4 (q), 114.2 (d), 123.4 (d), 127.5 
(d), 128.9 (s), 129.1 (d), 130.8 (d), 132.0 (d), 133.0 (s), 133.7 (s), 146.7 (s), 150.5 (s), 
150.7 (s), 164.6 (s), 190.7 (s). 
 
Anal. Calcd for C20H15Cl2NO2S: C, 59.41; H, 3.74; N, 3.46. Found: C, 59.22; H, 3.63; N, 
3.59. 
1-{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}-hex-5-en-1-one (151)  
 
O
N
Cl
Cl
SPh
151
 
 
 
 
was obtained by the PCC oxidation of 148 (170 mg, 0.462 mmol) in 83% yield as a 
yellow oil.  
 
IR (CHCl3) 1707, 1565, 1530, 1325 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 1.68-1.97 (m, 2H), 2.08-2.19 (m, 2H), 2.87 (t, 
2H, J = 7.3 Hz), 3.88 (s, 2H), 4.97-5.12 (m, 2H), 5.67-5.91 (m, 1H), 6.99 (s, 1H), 7.13-
7.42 (m, 5H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 22.3 (t), 32.8 (t), 36.1 (t), 43.4 (t), 115.6 (t), 123.9 
(d), 128.2 (d), 129.4 (d), 131.9 (d), 133.3 (s), 134.8 (s), 137.5 (d), 145.7 (s), 149.7 (s), 
150.3 (s), 202.7 (s). 
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DCI-MS m/z (rel intensity) 383 ([M + NH4]+, 82), 366 ([M + H]+, 100). 
HRMS (FAB) calcd for C18H18Cl2NOS (M + H)+ m/z 366.0486, found 366.0500. 
 
1-{2,6-Dichloro-4-[(phenylthio)methyl]pyridin-3-yl}-hept-6-en-1-one (152) 
 
O
N
Cl
Cl
SPh
152
 
 
 
 
was obtained by PCC oxidation of  149 (110 mg, 0.29 mmol) in 82% yield as a yellow 
oil. 
 
IR (CHCl3) 1702, 1567, 1532, 1329 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 1.38-1.61 (m, 2H), 1.65-1.85 (m, 2H), 1.92-2.21 
(m, 2H), 2.86 (t, 2H, J = 7.2 Hz), 3.87 (s, 2H), 4.92-5.13 (m, 2H), 5.72-5.91 (m, 1H), 
6.99 (s, 1H), 7.16-7.41 (m, 5H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 22.7 (t), 28.2 (t), 33.5 (t), 36.1 (t), 43.9 (t),  
115.0 (t), 124.0 (d), 128.2 (d), 129.4 (d), 131.9 (d), 133.3 (s), 134.9 (s), 138.1 (d), 145.6 
(s), 149.7 (s), 150.3 (s), 202.8 (s).  
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{2,6-Dichloro-4-[(phenylsulfinyl)methyl]pyridin-3-yl}-(4-methylphenyl)metha-none 
(126). 
N
Cl
Cl
SPh
O
Me
O
Me
N
Cl
Cl
SPh
O
(a) NaIO4
126123
(b) CH3CO3H
or
 
 
 
 
 
 
(a) To a slurry of 123 (430 mg, 1.10 mmol) in a 1:1 mixture of CH3OH and H2O (6 mL) 
was added NaIO4 (246 mg, 1.15 mmol) at 0 °C; then the mixture was warmed to room 
temperature. After 15-20 days 5 mL of CH2Cl2 was added. The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
The crude mass was purified over chromatography (EtOAc:petroleum ether 20:80) to 
give 380 mg (85%) of sulfoxide 126 as a white solid: mp 162-164 °C. 
 
IR (KBr) 1668, 1603, 1570, 1532, 1327, 1085, 1045 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 2.45 (s, 3H), 3.79 (d, 1H, J = 12.8 Hz), 3.92 (d, 
1H, J = 12.8 Hz), 7.15-7.85 (m, 10H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 21.8 (q), 60.4 (t), 123.7 (d), 125.2 (d), 129.3 
 (d), 129.7 (d), 129.9 (d), 131.7 (d), 133.4 (s), 133.5 (s), 142.5 (s), 143.5 (s), 145.9 (s), 
147.0 (s), 150.7 (s), 191.9 (s). 
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DCI-MS m/z (rel intensity) 421 ([M + NH4]+, 84), 404 ([M + H]+, 100).  
HRMS (FAB) calcd. for C20H16Cl2NO2S (M + H)+ m/z 404.0279, found 404.0262. 
 
Anal. Calcd for C20H15Cl2NO2S: C, 59.43; H, 3.73; N, 3.46. Found: C, 9.29; H, 3.78; N, 
3.52. 
 
(b) To a stirred solution of  123 (1 g, 2.57 mmol) in ether (20 mL) was added peracetic 
acid (32 wt %, 10 mL) at 0°C and stirring was continued for additional 10 min. Then the 
reaction mixture was refluxed for 20 min during which white precipitates are formed. The 
reaction mixture was triturated with excess of water (50 mL) and ether (50 mL) and the 
organic layer was separated. The aqueous layer was extracted with ether three times and 
the combined organic layer was wash with saturated NaHCO3 solution, dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude mass was 
purified over chromatography (EtOAc:petroleum ether 20:80) to give 720 mg (69.2 %) of 
sulfoxide 126 as a white solid: mp 162-164 °C. and remaining 100 mg of starting 
material. 
 
The 1H NMR of the product is identical with that obtained in (a). 
 
{2,6-Dichloro-4-[(phenylsulfinyl)methyl]pyridin-3-yl}-(phenyl)methanone (125) 
 
 
 
 62
NCl
Cl
SPh
O
O
125
 
 
 
 
 
 
 
was obtained by NaIO4 mediated oxidation of sulfide 122 (640 mg, 1.71 mmol) in 68% 
yield as a yellow oil. 
 
IR (KBr) 1665, 1605, 1577, 1532, 1333, 1085, 1045 cm-1. 
 
1H NMR (200 MHz CDCl3:CCl4 7:3) δ 3.74 (d, 1H, J = 12.9 Hz), 3.90 (d, 1H, J = 12.9 
Hz), 7.18 (s, 1H), 7.22-7.92 (m, 10H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 60.1 (t), 123.7 (d), 125.3 (d), 129.0 (d), 129.3 (d), 
129.7 (d), 131.8 (d), 133.3 (s), 134.8 (d), 135.8 (s), 142.5 (s), 143.7 (s), 147.0 (s), 150.9 
(s), 192.4 (s). 
 
Anal. Calcd for C19H13Cl2NO2S: C, 58.48; H, 3.35; N, 3.58. Found: C, 58.19; H, 3.13; N, 
3.68. 
 
{2,6-Dichloro-4-[(phenylsulfinyl)methyl]pyridin-3-yl}-(4-methoxyphenyl)meth-
anone (127)  
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was obtained by NaIO4 mediated oxidation of keto sulfide 124 (390 mg, 0.96 mmol) in 
91% yield as a white crystalline solid: mp 142-143 °C. 
 
IR (KBr) 1687, 1595, 1324, 1153, 1041 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3.73 (d, 1H, J = 12.9 Hz), 3.84 (s, 3H), 3.87 (d, 
1H, J = 12.9 Hz), 6.90 (d, 2H, J = 8.9 Hz), 7.14 (s, 1H), 7.24-7.58 (m, 5H), 7.72 (d, 2H, J 
= 8.69). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 55.5 (q), 60.4 (t), 114.3 (d), 123.7 (d), 125.1 (d), 
128.9 (s), 129.3 (d), 131.6 (d), 132.2 (d), 133.7 (s), 142.7 (s), 143.5 (s), 146.9 (s), 150.5 
(s), 164.8 (s), 190.5 (s).  
 
1-{2,6-Dichloro-4-[(phenylsulfinyl)methyl]pyridin-3-yl}hex-5-en-1-one (153)  
 
N
Cl
Cl
SPh
O
O
153
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 was obtained by NaIO4 mediated oxidation of keto sulfide 151 (90 mg, 0.246 mmol) by 
NaIO4 in 85% yield as a yellow oil. 
 
IR (CDCl3) 1702, 1530, 1328, 1123, 1085 cm-1. 
 
1H NMR (200 MHz, CDCl3) δ 1.78-1.95 (m, 2H), 2.12-2.27 (m, 2H), 2.96-3.02 (m, 2H), 
3.71 (d, 1H, J = 12.8 Hz), 4.12 (d, 1H, J = 12.9 Hz), 4.99-5.11 (m, 2H), 5.71-5.88 (m, 
1H), 6.83 (s, 1H), 7.42-7.58 (m, 5H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 22.6 (t), 32.7 (t), 43.6 (t), 59.0 (t), 115.5 (t), 123.9 
(d), 125.3 (d), 129.5 (d), 132.0 (d), 136.0 (s), 137.6 (d), 141.7 (s), 142.0 (s), 146.0 (s), 
150.3 (s), 203.4 (s). 
 
Anal. Calcd for C18H17Cl2NO2S: C, 56.56; H, 4.47; N, 3.66. Found: C, 56.69; H, 4.53; N, 
3.51. 
 
1-{2,6-Dichloro-4-[(phenylsulfinyl)methyl]pyridin-3-yl}hept-6-en-1-one (154) 
 
N
Cl
Cl
SPh
O
O
154
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was obtained by NaIO4 mediated oxidation of keto sulfide 152 (100 mg, 0.263 mmol) by 
NaIO4 in 77% yield as yellow oil. 
 
IR (CHCl3) 1702, 1633, 1563, 1392, 1094, 1048 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 1.38-2.19 (m, 6H), 2.81-3.09 (m, 2H), 3.72 (d, 
1H, J = 12.9 Hz), 4.11 (d, 1H, J = 12.9 Hz), 4.89-5.16 (m, 2H), 5.69-5.91 (m, 1H), 6.85 
(s, 1H), 7.41-7.82 (m, 5H). 
 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 22.9 (t), 28.2 (t), 33.6 (t), 43.7 (t), 57.7 (t), 114.9 
(t), 126.2 (d), 128.4 (d), 129.7 (d), 134.7 (d), 136.5 (s), 138.2 (s), 138.3 (d), 139.2 (s), 
146.5 (s), 150.6 (s), 203.3 (s). 
 
Anal. Calcd for C19H19Cl2NO2S; C, 57.57; H, 4.82; N, 3.53. Found: C, 57.80; H, 5.01; N, 
3.51. 
 
General procedure for Pummerer-Diels-Alder reaction 
 
Padwa’s conditions (Ac2O/ p-TsOH): A mixture containing acetic anhydride (10 
mmol), appropriate dienophile (4 mmol), and a catalytic amount of p-toluenesulfonic acid 
in dry toluene (10 mL) was heated at reflux under argon. To this mixture was added a 
toluene solution of keto-sulfoxide (1 mmol) dropwise over a period of 10 min. After 
addition was complete the yellow mixture was heated at reflux for an additional 1 h. The 
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reddish yellow solution was cooled and washed with saturated aqueous NaHCO3 
solution. The organic layer was concentrated and purified by preparative layer 
chromatography. 
 
Modified conditions ((C3F7CO)2O/ p-TsOH): A mixture containing heptafluorobutyric 
anhydride (10 mmol), appropriate dienophile (4 mmol), and a catalytic amount of p-
toluenesulfonic acid was heated at reflux under argon. To this mixture was added keto-
sulfoxide (1 mmol) in dry toluene dropwise over a period of 10 min. After complete 
addition, the yellow mixture was heated at reflux for an additional 1 h. The reddish 
yellow solution was cooled and washed with saturated NaHCO3 solution. The organic 
layer was concentrated and purified by preparative layer chromatography. 
 
Dimethyl 3,5-dichloro-1-(4-methylphenyl)-8-(phenylthio)-11-oxa-4-azatricyclo- 
[6.2.1.02,7] - undeca-2,4,6-triene-9,-10-dicarboxylate (133)  
 
 
SPh
O
Cl
Cl
N
Me
N
CO2Me
CO2Me
O
SPh
Cl
Cl
Me
(C3F7CO)2O, p-TsOH, 
dimethyl maleate, PhMe
 reflux, 1h.
126 133
O
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was prepared by the treatment of ketosulfoxide 126 (100 mg, 0.247 mmol) with dimethyl 
maleate (0.124 mL, 1 mmol) under modified conditions in 37% yield as a yellowish 
white solid: mp 199-200 °C. 
 
IR (KBr) 1742, 1633, 1595, 1336 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 2.41 (s, 3H), 3.56 (s, 6H), 3.58 (d, 1H, J = 11 
Hz), 4.14 (d, 1H, J = 11 Hz), 7.19-7.69 (m, 10H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ  21.4 (q), 52.0 (q), 52.4 (q), 52.6 (d), 53.6 (d), 
90.0 (s), 93.7 (s), 118.0 (d), 128.1 (d), 129.2 (d), 129.6 (d), 131.1 (s), 135.5 (d), 137.8 (s), 
139.4 (s), 143.8 (s), 148.8 (s), 157.5 (s), 167.7 (s), 169.0 (s). 
 
FAB MS m/z (rel intensity) 530 ([M + H]+, 11), 386 (3), 273 (3), 235 (6), 165 (4). 
HRMS (FAB) calcd for C26H22Cl2NO5S (M+H)+ m/z 530.0596, found 530.0589. 
 
Anal. Calcd for C26H21Cl2NO5S: C, 58.88; H, 3.98; N, 2.64. Found: C, 58.65; H, 3.94; N, 
2.87. 
 
Dimethyl 3,5-dichloro-1-phenyl-8-(phenylthio)-11-oxa-4-azatricyclo[6.2.1.02,7]-
undeca-2,4, 6-triene-9,10-dicarboxylate (132)  
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was prepared in a similar manner (modified conditions) from keto sulfoxide 125 (100 mg, 
0.26 mmol) in 33% yield as a yellowish white solid: mp 174-175 °C. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3.57 (s, 6H), 3.61 (d, 1H, J = 11.2 Hz), 4.16 (d, 
1H, J = 11.2 Hz), 7.25-7.70 (m, 11H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 51.9 (q), 52.3 (q), 52.5 (d), 53.5 (d), 89.8 (s), 93.7 
(s), 117.9 (d), 127.7 (s), 127.9 (s), 128.0 (d), 128.4 (d), 129.1 (d), 129.4 (d), 129.5 (d), 
133.9 (s), 135.3 (d), 137.7 (s), 148.7 (s), 157.2 (s), 167.6 (s), 168.9 (s). 
 
Anal. Calcd for C25H19Cl2NO5S: C, 58.15; H, 3.70; N, 2.71. Found: C, 58.45; H, 3.38; N, 
2.91. 
Dimethyl 3,5-dichloro-1-(4-methoxyphenyl)-8-(phenylthio)-11-oxa-4-azatricy-clo-
[6.2.1. 02,7]undeca-2,4,6-triene-9,10-dicarboxylate (134) 
 
N
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 was prepared in a similar manner (modified conditions) from keto sulfoxide 127 (110 mg, 
0.26 mmol) in 40% yield as a white solid: mp 164-166 °C. 
 
IR (KBr) 1743, 1596, 1339, 1246 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3.55 (s, 3H), 3.56 (s, 3H), 3.57 (d, 1H, J = 10.9 
Hz), 3.89 (s, 3H), 4.13 (d, 1H, J = 10.9 Hz), 6.89-7.62 (m, 10H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 51.9 (q), 52.3 (q), 52.5 (d), 53.5 (d), 55.0 (q), 
 89.7 (s), 93.4 (s), 113.8 (d), 117.9 (d), 125.8 (s), 128.0 (s), 129.1 (d), 129.4 (d), 129.5 
(d), 135.4 (d), 137.6 (s), 143.7 (s), 148.7 (s), 157.3 (s), 160.4 (s), 167.5 (s), 168.9 (s). 
 
Anal. Calcd for C26H21Cl2NO6S: C, 57.15; H, 3.87; N, 2.56. Found: C, 56.98; H, 3.97; N, 
2.43. 
 
 [2,6-Dichloro-3-(4-methoxybenzoyl)pyridin-4-yl](phenylthio) methyl acetate (136) 
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was obtained along with 127 via a Pummerer reaction of keto-sulfoxide 127 under 
Padwa’s conditions as a white crystalline solid: mp 123-124 °C. 
 
IR (KBr) 1763, 1661, 1573, 1569, 1318 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 1.98 (s, 3H), 3.88 (s, 3H), 6.75-7.91 (m, 11H). 
 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 20.6 (q), 55.5 (q), 77.4 (d), 114.2 (d), 120.6 (d), 
128.8 (s), 129.2 (d), 129.5 (d), 129.9 (s), 130.7 (s), 132.3 (d), 134.6 (d), 147.2 (s), 149.7 
(s), 150.7 (s), 164.8 (s), 168.3 (s), 189.9 (s). 
 
LCMS m/z (rel intensity) 462 ([M + H]+, 8), 402 ([M - OAc]+, 100), 292 ([M - OAc- 
PhSH]+, 71). 
 
Anal. Calcd for C22H17Cl2NO4S: C, 57.15; H, 3.70; N, 3.02. Found: C, 57.29; H, 3.58; N, 
2.97. 
4,6-dichloro-3-(4-methoxyphenyl)-1-(phenylthio)furo[3,4-c]pyridine (131) 
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To a mixture of heptafluorobutyric anhydride (0.47 mL, 1.9 mmol) and a catalytic 
amount of p-toluenesulfonic acid in 5 mL of toluene heated at reflux was added a toluene 
solution of keto-sulfoxide 127 (80 mg, 0.19 mmol) over a period of 10 min under argon 
atmosphere. The bright yellow mixture was allowed to reflux for an additional 1h, 
concentrated under reduced pressure, and purified by chromatography (EtOAc:petroleum 
ether 5:95) quickly. The intermediate 4,6-dichloro-3-(4-methoxyphenyl)-1-
(phenylthio)furo[3,4-c]pyridine (131) (40 mg, 52% yield) was obtained as a yellow oil. 
 
IR (CDCl3) 1604, 1508, 1259 cm-1. 
 
1H NMR (200 MHz, CDCl3) δ 3.88 (s, 3H), 7.01 (d, 2H, J = 8.8 Hz), 7.11-7.25 (m, 5H), 
7.31 (s, 1H), 7.75 (d, 2H, J = 8.8 Hz).  
 
Methyl 3,5-dichloro-1-(4-methoxyphenyl)-8-(phenylthio)-11-oxa-4-azatricyclo 
[6.2.1.02,7]- undeca-2,4,6-triene-10-carboxylate (140) 
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To a well-stirred toluene (5 mL) solution of 131 (40 mg, 0.099 mmol) was added 
methyl acrylate (0.068 mL, 0.76 mmol) and the mixture was heated at reflux for 1 h 
under argon. The resulting yellow solution was triturated with 5 mL of ether, washed 
with H2O, and concentrated under reduced pressure. Purification of the crude product by 
preparative layer chromatography yielded a mixture of two isomers (18 mg, 36% yield) 
which on crystallization gave 140 as the major isomer: mp 117-119 °C. 
 
IR (KBr) 1736, 1575, 1320, 1220 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 2.12 (dd, 1H, J1 = 12.2 Hz, J2 = 4.2 Hz), 2.58 
(dd, 1H, J1 = 12.2 Hz, J2 = 10.2 Hz), 3.57 (s, 3H), 3.86 (s, 3H), 3.91 (dd, 1H, J1 = 10.2 
Hz, J2 = 4.2 Hz), 6.91-7.10 (m, 2H), 7.16 (s, 1H), 7.25-7.39 (m, 3H), 7.51-7.68 (m, 4H). 
 
13C NMR (50 MHz, CDCl3) δ 39.8 (t), 47.7 (d), 52.4 (q), 55.3 (q), 90.4 (s), 92.8 (s), 
113.8 (d), 114.9 (d), 125.9 (s), 129.0 (d), 129.1 (d), 129.3 (s), 130.0 (d), 134.2 (d), 136.7 
(s), 143.7 (s), 149.6 (s), 160.0 (s), 160.4 (s), 170.9 (s). 
When the reaction was conducted in one pot (cf. modified conditions), the overall yield 
of products 140 and 141 was higher (46%).  
 
1,3-Dichloro-5-(phenylthio)-8,9-dihydro-7H-cyclopenta[h]isoquinoline (159)  
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was prepared in a similar manner (modified conditions) from keto-sulfoxide 153 (50 mg, 
0.13 mmol) in 67% yield as a white crystalline solid: mp 109-110 °C. 
 
IR (KBr) 1577, 1538, 1278, 1177 cm-1. 
 
1H NMR (200 MHz, CDCl3) δ 2.20 (quint, 2H, J = 7.6 Hz), 3.03 (t, 2H, J = 7.7 Hz), 3.74 
(t, 2H, J = 7.5 Hz), 7.01-7.45 (m, 5H), 7.78 (s, 1H), 8.20 (s, 1H). 
 
13C NMR (50 MHz, CDCl3) δ 24.3 (t), 33.3 (t), 36.4 (t), 118.4 (d), 124.9 (s), 126.8 (d), 
128.1 (s), 129.2 (d), 129.3 (d), 134.3 (s), 135.5 (d), 140.3 (s), 141.5 (s), 142.7 (s), 146.0 
(s), 149.9 (s). 
 
Anal. Calcd for C18H13Cl2NS: C, 62.42; H, 3.78; N, 4.04. Found: C, 62.24; H, 3.55; N, 
4.29.  
 
1,3-Dichloro-5-(phenylthio)-7,8,9,10-tetrahydrobenzo-[h]isoquinoline (160) 
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was prepared from keto sulfoxide 154 (40 mg, 0.1 mmol) by similar methodology in 56% 
yield as a white crystalline solid: mp 89-91 °C. 
 
IR (KBr) 1574, 1539, 1333, 1112, 1025 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 1.78-1.98 (m, 4H), 2.79-3.05 (m, 2H), 3.45-3.63 
(m, 2H), 7.01-7.41 (m, 5H), 7.60 (s, 1H), 8.17 (s, 1H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 21.7 (t), 23.2 (t), 31.1 (t), 31.2 (t), 118.3 (d), 
126.8 (d), 127.3 (s), 127.9 (s), 129.0 (d), 129.4 (d), 135.7 (s), 136.1 (s), 138.5 (s), 140.8 
(d), 141.0 (s), 142.8 (s) 149.0 (s). 
 
FAB MS m/z (rel intensity) 360 ([M + H]+, 21), 273 (3), 235 (6), 165 (5). 
HRMS (FAB) calcd for C19H16Cl2NS (M + H)+ m/z 360.0380, found 360.0381. 
 
Anal. Calcd for C19H15Cl2NS: C, 63.34; H, 4.19; N, 3.88. Found: C, 62.98; H, 4.35; N, 
4.29.  
 
(2,6-Dichloro-3-hex-5-enoylpyridin-4-yl)(phenylthio)methyl acetate (161) 
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 O
N
Cl
Cl
SPhO
O
N
Cl
Cl
SPh
OAc(CH3CO)2O
153 161
p-TsOH
 
 
 
 
A mixture containing acetic anhydride (0.05 ml, 0.5 mmol) and a catalytic amount of p-
toluenesulfonic acid in dry toluene (5 mL) was heated at reflux under argon. To this 
mixture was added a toluene solution of keto-sulfoxide 153 (20 mg, 0.052 mmol) 
dropwise over a period of 10 min. After addition was complete the yellow mixture was 
heated at reflux for an additional 1 h. The reddish yellow solution was cooled and washed 
with saturated aqueous NaHCO3 solution. The organic layer was concentrated and 
purified by preparative layer chromatography gave 14 mg (63%) of 161 as.a colourless 
liquid. 
 
IR (CH2Cl2) 1756, 1701, 1572, 1015 cm-1. 
1H NMR (200 MHz, CDCl3) δ 1.78-1.1.98 (m, 2H), 2.12 (s, 3H), 2.02-2.24 (m, 2H), 
2.91-3.08 (m, 2H), 4.91-5.09 (m, 2H), 5.62-5.91 (m, 1H), 6.85 (s, 1H), 7.02 (s, 1H), 7.31-
7.48 (m, 5H). 
13C NMR (300 MHz, CDCl3) δ20.9 (q), 22.3 (t), 32.8 (t), 43.3 (t), 76.5 (d), 115.5 (t), 
120.6 (d), 129.2 (s), 129.4 (d), 130.0 (d), 132.2 (s), 135.0 (d), 137.7 (d), 145.3 (s), 148.4 
(s), 150.6 (s), 168.7 (s), 202.3 (s). 
 
HRMS calcd for C20H20Cl2NO3S (M+ H)+ m/z 424.0541, found 424.0542.  
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Dimethyl 1,3-dichloro-8-(4-methylphenyl)-5-(phenylthio)isoquinoline-6,7-dicar-
boxylate (164)  
 
N
Cl
Cl
SPh
CO2Me
CO2Me
Me
O DBU
N
Cl
Cl
SPh
CO2Me
CO2Me
Me
tol, reflux,
    2 h
133 164
55%
 
 
 
 
 
To a stirred solution of oxa-bridged diester 133 (80 mg, 0.15 mmol) in 5 mL of 
toluene was added DBU (0.22 mL, 1.5 mmol) dropwise at room temperature. The 
mixture was heated at reflux for 1.5 h giving a reddish yellow solution, cooled, washed 
with 10% HCl, dried over anhydrous Na2SO4, and concentrated under reduced pressure. 
Chromatographic purification (EtOAc:petroleum ether 10:90) gave 42 mg (55%) of  164 
as a yellow crystalline solid: mp 160-161 °C. 
 
IR (KBr) 1735, 1585, 1363, 1333, 1062 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 2.44 (s, 3H), 3.47 (s, 3H), 3.87 (s, 3H), 7.08-7.40 
(m, 9H), 8.36 (s, 1H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 21.5 (q), 52.5 (q), 53.0 (q), 118.9 (d), 125.0 (s), 
127.1 (d), 127.8 (s), 128.6 (d), 128.7 (d), 129.5 (d), 133.5 (s), 134.3 (s), 135.2 (s), 138.5 
(s), 141.4 (s), 141.6 (s), 142.8 (s), 146.0 (s), 151.8 (s), 166.6 (s), 166.9 (s). 
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FAB MS m/z (rel intensity) 512 ([M + H]+, 21), 480 ([M - OCH3]+, 9), 412 (2), 273 (3), 
235 (6), 165 (5). 
 
Anal. Calcd for C26H19Cl2NO4S: C, 60.95; H, 3.73; N, 2.73. Found: C, 60.92; H, 3.85; N, 
2.89.  
Dimethyl 1,3-dichloro-8-phenyl-5-(phenylthio)-isoquinoline-6,7-dicarboxylate (163) 
 
N
SPh
CO2Me
CO2MeCl
Cl
163
 
 
 
 
was prepared similarly by treatment of 132 (150 mg, 0.29 mmol) with DBU in 53% 
yield: mp 178-179 °C. 
 
IR (KBr) 1737, 1584, 1375, 1316, 1062 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 3. 43 (s, 3H), 3.88 (s, 3H), 7.15-7.32 (m, 6H), 
7.35-7.48 (m, 4H), 8.37 (s, 1H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 52.5 (q), 53.0 (q), 119.0 (d), 124.8 (s), 127.2 (d), 
127.9 (d), 128.0 (s), 128.6 (d), 128.8 (d), 129.5 (d), 129.6 (d), 133.4 (s), 135.0 (s), 137.3 
(s), 141.1 (s), 141.6 (s), 142.7 (s), 146.2 (s), 151.7 (s), 166.6 (s), 166.9 (s).  
Dimethyl 1,3-dichloro-8-(4-methoxyphenyl)-5-(phenylthio)isoquinoline-6,7-dicarbo-
xylate (165)  
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 N
SPh
CO2Me
CO2MeCl
Cl
OMe
165
 
 
 
 
 
was prepared by similar treatment of 134 (60 mg, 0.11 mmol) with DBU in 45% yield as 
a white crystalline solid: mp 190-192 °C. 
 
IR (KBr) 1740, 1554, 1365, 1332, 1062 cm-1. 
 
1H NMR (200 MHz, CDCl3) δ 3.51 (s, 3H), 3.87 (s, 6H), 6.91-7.01 (m, 2H), 7.12-7.34 
(m, 7H), 8.38 (s, 1H). 
Anal. Calcd for C26H19Cl2NO5S: C, 59.10; H, 3.62; N, 2.65. Found: C, 59.32; H, 3.59; N, 
2.55. 
One pot synthesis of 165 
A mixture containing heptafluorobutyric anhydride (0.25 mL, 1.01 mmol), 
dimethyl maleate (0.048 mL, 0.38 mmol), and a catalytic amount of p-toluenesulfonic 
acid in toluene (5 mL) was heated at reflux under argon. To this mixture was added keto-
sulfoxide 127 (40 mg, 0.095 mmol) in dry toluene dropwise over a period of 10 min. 
After complete addition, the yellow mixture was heated at reflux for an additional 1 h. 
The reddish yellow solution was cooled to room temperature and then DBU (0.45 ml, 
3.03 mmol) was added. The reaction mixture was heated to reflux for additional 1h. Then 
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the reaction mixture was cooled, washed with 10% HCl, dried over anhydrous Na2SO4, 
and concentrated under reduced pressure.  Chromatographic purification 
(EtOAc:petroleum ether 10:90) gave 10 mg (20 % from 127) of  165 as a white 
crystalline solid. 
1H NMR of the product is identical with the above. 
 
Dimethyl 3,5-dichloro-1-(4-methylphenyl)-8-(phenylsulfonyl)-11-oxa-4-azatri-cyclo 
[6.2.1. 02,7]undeca-2,4,6-triene-9,10-dicarboxylate (166).  
 
N
Cl
Cl
SPh
Me
O
NaIO4
N
Cl
Cl
SO2Ph
Me
O
133 166
94%
RuCl3.x H2O
CO2Me
CO2Me
CO2Me
CO2Me
 
 
 
 
 
 
To a mixture of oxa-bridged diester 133 (140 mg, 0.264 mmol) and NaIO4 (240 
mg, 1.12 mmol) in a 10 mL mixture of CH3CN, CCl4, H2O (1:1:3) was added a catalytic 
amount of RuCl3.xH2O. The solution was stirred at room temperature for 2 h and then 
diluted with 5 mL of CH2Cl2. The resulting two layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3 × 5 mL). The combined organic layer was dried over 
anhydrous Na2SO4 and concentrated. The crude black residue was diluted with 20 mL of 
diethyl ether and filtered through a short column of silica gel, which on concentration 
gives 140 mg (94%) of 166 as a white crystalline solid: mp 202-203 °C. 
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 IR (KBr) 1750, 1591, 1333, 1164 cm-1. 
 
 1H NMR (200 MHz, CDCl3) δ 2.36 (s, 3H), 3.58 (s, 3H), 3.66 (s, 3H), 4.21 (d, 1H, J = 
11.2 Hz), 4.29 (d, 1H, J = 11.2 Hz), 7.12 (s, 4H), 7.51-7.99 (m, 5H), 7.93 (s, 1H). 
13C NMR (50 MHz, CDCl3) δ 21.3 (q), 50.8 (d), 52.6 (q), 53.0 (d), 91.8 (s), 98.0 (s), 
118.3 (d), 127.8 (d), 129.2 (d), 129.3 (d), 129.8 (s), 130.2 (d), 134.7 (s), 135.1 (d),  
137.6 (s), 140.0 (s), 144.5 (s), 149.2 (s), 152.8 (s), 167.2 (s), 168.4 (s). 
 
DCI-MS m/z (rel intensity) 579 ([M + NH4]+, 14), 562 ([M + H]+, 100). 
HRMS (FAB) calcd for C26H22Cl2NO7S (M+ H)+ m/z 562.0494, found 562.0507.  
Dimethyl 1,3-dichloro-5-hydroxy-8-(4-methylphenyl)-isoquinoline-6,7-dicarbo-
xylate (167) 
 
N
Cl
Cl
SO2Ph
Me
O DBU
N
Cl
Cl
OH
CO2Me
CO2Me
Me
166
77%
167
CO2Me
CO2Me
 
 
 
 
 
To a stirred solution of sulfone 166 (140 mg, 0.25 mmol) in 10 mL of toluene was 
added DBU (0.075 mL, 0.5 mmol) at room temperature and the mixture was then heated 
to reflux for 1 h under argon. The reddish yellow solution was washed with 10% HCl, 
dried over anhydrous Na2SO4, and then concentrated under reduced pressure. The residue 
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on chromatographic purification (EtOAc:petroleum ether 30:70) gave 80 mg (77%) of 
167 as a white crystalline solid: mp 209 °C. 
 
 IR (KBr) 3441, 3018, 1732, 1612, 1558, 1199 cm-1. 
 
1H NMR (200 MHz, CDCl3) δ 2.40 (s, 3H), 3.47 (s, 3H), 3.97 (s, 3H), 7.08 (d, 2H, J = 
8.1 Hz), 7.17 (d, 2H, J = 8.0 Hz), 8.31 (s, 1H), 12.42 (s, 1H). 
13C NMR (50 MHz, CDCl3) δ 21.4 (q), 51.9 (q), 53.6 (q), 106.0 (s), 116.2 (d), 126.4 (s), 
128.2 (d), 128.7 (s), 130.8 (d), 133.4 (s), 134.3 (s), 137.9 (s), 143.7 (s), 144.4 (s), 150.4 
(s), 158.6 (s), 167.7 (s), 169.3 (s). 
 
DCI-MS m/z (rel intensity) 437 ([M + NH4]+, 7), 420 ([M + H]+, 100). 
HRMS (FAB) calcd for C20H16Cl2NO5 (M + H)+ m/z 420.0406, found 420.0410.  
Dimethyl 1,3-Dichloro-5-methoxy-8-(4-methylphenyl)-isoquinoline-6,7-dicarbo-
xylate (168) 
 
CH2N2
N
Cl
Cl
OMe
CO2Me
CO2Me
Me
N
Cl
Cl
OH
CO2Me
CO2Me
Me
167 168
89%
 
 
 
 
 
Diazomethane generated from N-nitroso N-methyl urea (236 mg, 2.29 mmol) and 
40% aqueous KOH in diethyl ether was added to 120 mg (0.28 mmol) of 167 at 0 °C. 
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After vigorous hand stirring the ice bath was removed and the reaction mixture was left at 
room temperature overnight. Ether was removed under reduced pressure and the residue 
on chromatographic purification (EtOAc:petroleum ether 20:80) gave 110 mg (89%) of 
168 as a white solid: mp 135-137 °C. 
 
IR (KBr) 1740, 1560, 1338, 1208 cm-1. 
 
1H NMR (200 MHz, CDCl3:CCl4 7:3) δ 2.41 (s, 3H), 3.44 (s, 3H), 3.93 (s, 3H), 4.07 (s, 
3H), 7.09 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 8.0 Hz), 8.03 (s, 1H). 
13C NMR (50 MHz, CDCl3:CCl4 7:3) δ 21.4 (q), 52.2 (q), 53.0 (q), 63.7 (q), 115.0 (d), 
124.1 (s), 125.4 (s), 128.3 (d), 130.0 (d), 134.1 (s), 134.4 (s), 134.6 (s), 136.5 (s), 137.9 
(s), 144.9 (s), 151.3 (s), 153.0 (s), 165.4 (s), 167.0 (s). 
 
Anal. Calcd for C21H17Cl2NO5: C, 58.09; H, 3.94; N, 3.22. Found: C, 58.19; H, 3.89; N, 
3.41. 
5,7-Dichloro-9-methoxy-4-(4-methylphenyl)furo[3,4-g]-isoquinolin-3(1H)-one (169) 
 
N
Cl
Cl
OMe
CO2Me
CO2Me
Me
N
Cl
Cl
OMe
Me
O
O
169
DIBAL-H
90%
168
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To a stirred solution of 168 (50 mg, 0.11 mmol) in 10 mL of CH2Cl2 cooled to -78 
°C was added 0.25 mL of DIBAL-H (1.0 M solution in toluene) dropwise under argon. 
The resulting mixture was stirred for 30 min at the same temperature and then allowed to 
warm to 0 °C. The reaction mixture was quenched with 2 mL of saturated aqueous 
NH4Cl solution and stirred for 30 min, then it was acidified with 20 % HCl and two 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduce 
pressure and on preparative layer chromatographic purification gave 40 mg (90%) of 169 
as a white crystalline solid: mp 252-254 °C. 
 
IR (KBr) 1779, 1573, 1460, 1333 cm-1.  
 
1H NMR (200 MHz, CDCl3) δ 2.45 (s, 3H), 4.19 (s, 3H), 5.59 (s, 2H), 7.01-7.35 (m, 4H), 
8.14 (s, 1H). 
13C NMR (50 MHz, CDCl3) δ 21.5 (q), 59.9 (q), 65.8 (t), 114.8 (d), 124.5 (s), 125.7 (s), 
128.5 (d), 129.0 (s), 129.3 (d), 131.7 (s), 137.0 (s), 137.7 (s), 138.2 (s), 145.3 (s), 147.8 
(s), 152.5 (s), 167.3 (s). 
 
FAB MS m/z (rel intensity) 374 ([M + H]+, 8), 329 ([M - CO2]+, 3) 273 (6), 242 (5), 165 
(6). 
HRMS (FAB) calcd for C19H14Cl2NO3 (M + H)+ m/z 374.0351, found 374.0351.  
Anal. Calcd for C19H13Cl2NO3: C, 60.98; H, 3.49; N, 3.74. Found: C, 60.71; H, 3.32; N, 
3.85. 
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Chapter 2 
 
A Formal Imine-Tautomerisation Route for the Generation 
and Trapping of Pyridine o-Quinodimethanes: Synthesis of 
Conformationally Restricted Analogues of Nicotine 
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1. Introduction 
 
In 1957, Cava and Napier1 first reported the generation of o-quinodimethane 2 as 
a reaction intermediate in the conversion of α,α,α´,α´- tetrabromo-o-xylene (1) to trans-
1,2-dibromobenzocyclobutene (3) (Scheme 1). Since then, many methods for the 
generation of o-quinodimethanes have been developed and their characterization, 
structure, and chemical reactivity have been thoroughly studied.2 
Scheme 1 
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In contrast, and in spite of their considerable potential in synthesis, heterocyclic 
analogues of o-quinodimethanes have received much less attention. However, in the 
last 15 years or so this situation has changed considerably and the ground rules for 
producing and handling such species have become much clearer. 2b, 3 The methods 
used to prepare hetero-o-quinodimethanes are summarized in Scheme 2. 
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In the previous chapter, we have discussed our progress on the generation and 
trapping of furopyridines towards the synthesis of some biologically important 
molecules. One of the successful ventures in this regard has been the intramolecular 
Diels-Alder trapping of furopyridines which provides a novel route for the synthesis of 
conformationally restricted anabasines. However, this route failed for the synthesis of 
conformationally restricted nicotines. This failure prompted Sarkar et al. from this 
laboratory to develop an alternative route via the generation and trapping of pyridine o-
quinodimethanes for the synthesis of conformationally restricted nicotines and to study 
their pharmacological activities.  
In the last several decades, pharmacologists and chemists have focused an 
immense amount of research on the nicotinic receptor. At this juncture an overview on 
nicotinic acetylcholine receptors, the various nicotinic ligands with emphasis on 
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conformationally restricted nicotines and pharmacophoric models is presented here as it 
is relevant to this chapter. 
1.1. Nicotinic acetylcholine receptors (nAChRs)  
Neuronal nicotinic acetylcholine receptors (nAChRs) are a family of ligand gated 
ion channels found in the central and peripheral nervous systems that regulate synaptic 
activity.4 nAChRs are a key target in drug discovery for a number of diseases, including 
Alzheimer’s and Parkinson’s disease, and have been widely discussed and investigated.5
The nicotinic acetylcholine receptors (nAChRs) have a pentameric structure and 
are composed of subunits that have distinct and overlapping expression patterns in 
subsets of neurons.6, 7 Figure 1 illustrates a cross-section of cell membrane and 
pentameric nAChRs that protrude through the membrane. From the cross section of the  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
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receptor one can see the ion channel pore in the closed state. Nicotine/acetylcholine binds 
to the receptor and opens the ion channel pore which affects the membrane potential and 
probability of depolarization. 
Biochemical and molecular studies show that neuronal nicotinic acetylcholine 
receptors generally appear to consist of only two types of subunits ― ligand binding α 
subunit (characterized by the presence of a pair of adjacent cysteine residues close to the 
acetylcholine binding site in the N-terminal domain) and structural β subunits (compared 
to the muscle nAChR which is comprised of four different subunits, α, β, δ and ε or γ).6 
The neuronal nicotinic acetylcholine receptors are generally believed to have a 
stoichiometry of two α subunits and three β subunits. Genes that are similar in sequence 
to the genes encoding the subunits of nicotinic acetylcholine receptors (nAChRs) at the 
neuromuscular junction (muscle) encode the subunits of neuronal nAChRs. To date, nine 
neuronal nAChR α gene (α2-α10) and three nAChR β genes (β2 – β4) have been cloned.7, 
8 These neuronal nAChR genes could generate a vast number of pentameric combinations 
of the receptor. Homo-oligomeric receptors can be assembled from α7, α8 or α9 subunits; 
combining α7 and α8 could generate hetero-oligomeric receptors (Fig. 2).9  
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Figure 2. Major nAChR subtypes present in the central nervous system (CNS) and 
peripheral nervous system (PNS). Black circles represent putative agonist binding sites at 
subunit interfaces.  
nAChR subtypes are found in different locations of the central and peripheral 
nervous system and have been assigned different pharmacological functions. For 
instance, the α4β2 and α4β4 subtypes appear to play a role in cognition, 
neurodegeneration, pain, anxiety, and depression; the α3β2 subtype plays a role in 
dopamine release and Parkinson’s disease; the α7 plays a role in GABA release; the α9 
plays a role in auditory function and development; and the α3β4 plays a role in 
norepinephrine release and cardiovascular and gastrointestinal action.7d Recent clinical 
studies have indicated potential efficacy of nicotine in the treatment of depression and 
normalization of auditory gating deficit in schizophrenic patients. Studies in animals and 
humans have shown consistent improvements in sustained attention. Deficits in attention 
are prevalent in ageing and in early stages of Alzheimer’s disease (AD) as well as in 
Attention Deficit Hyperactivity Disorder (ADHD). Thus, the therapeutic potential of 
nAChR agonists, such as nicotine, in Alzheimer’s, Parkinson’s disease, Tourette’s 
syndrome, and pain is being recognized.10-15
 
1.2. Nicotinic ligands and their synthesis 
Critical limitations for the potential use of nicotine as a therapeutic are peripheral 
side effects that are due to the non-selective profile of nicotine. The side effects are 
observed in the gastrointestinal system, in the cardio-vascular system, and body 
temperature and nicotine is a relatively toxic compound that is reinforcing and likely 
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responsible for the addictive properties of tobacco.16 Compounds that target specific 
subtypes in the CNS may not induce these side effects and yet retain the beneficial effects 
of nicotine. During the past 3 decades or so, vast efforts have been made to synthesize 
novel subtype selective nicotinic ligands 5, 11, 17-19
 
Based on the structure and 
conformation of nicotine two approaches are followed which are discussed here-in-after. 
Pyridine and pyrrolidine modified analogues 
Numerous pyridine and pyrrolidine modified analogues of nicotine were 
synthesized and their binding assays carried out.5b, 18 Introduction of substituents at 3´, 4´, 
or 5´-positions of the pyrrolidine ring generally results in unfavourable binding. It may be 
mentioned here that one series of agonists from the Abbott Laboratories exemplified by 
ABT 418 (now available from Sigma-Aldrich) has entered clinical trials to treat the 
cognitive deficits associated with Alzhiemer disease.20  
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Conformationally restricted analogues 
During the past two decades or so a great stride has been made to probe the role 
of particular conformations on the pharmacological properties of important biologically 
active molecules such as amino acids,21 peptides,22
 
sugars,23
 
nucleosides,24
 
nucleotides,23a, 
25  nucleic acids,26 
 
vitamines,27 
 
raloxifene,28
 
dihydropyrimidines,29 etc. In almost all these 
studies the parent molecule is modified in such a fashion that its original conformational 
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mobility is severely limited to one particular conformation. For tobacco alkaloids nicotine 
(4) and anabasine (5) (Figure 3), the synthesis and evaluation of conformationally 
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Figure 3 
restricted analogues might provide informations on the steric and electronic requirements 
for optimal binding and functional potency, thus allowing development of a foundation 
for the rational design of new potent and selective neuronal nicotinic acetylcholine 
receptor ligands.30 It should be pointed out that the conformationally frozen nicotinic 
ligands can improve the affinity and specificity for a receptor primarily as a result of 
reducing the entropic loss upon binding. 
  Chemists from far-flung laboratories have already generated an array of 
conformationally constrained nicotines and anabasines by tethering the two rings present 
in each of 4 and 5 with a short chain containing only carbon atoms or a combination of 
carbon and hetero atoms. A list of constrained nicotines and anabasines is shown in 
Figure 4. 
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Various synthetic strategies were adopted for the synthesis of these types of 
ligands. In 1978 Catka and Leete31 reported the synthesis of 6 as shown in Scheme 3; 
however, no biological assay of this compound was made. In 1983, Chavdarian et al.32  
Scheme 3 
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Reagents: (i) morpholine, NaCN, HClO4; (ii) tBuO-K+, CH2=CH-CH2CN; (iii) H+; (iv) Ra-Ni; (v) 
(a) n-BuLi, CO2; (b) 1-ethyl-3(3-dimethylaminopropyl)carbodiimide; (vi) BH3.THF. 
 
reported the synthesis of 7 as well as the methylated analogue 8 (Scheme 4). In 1988,  
Scheme 4 
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Reagents: (i) (a) LDA, (b) nitroethylene; (ii) Ra Ni, H2; (iii) NaBH3CN; (iv) CH2O, NaBH3CN. 
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Kanne and co-workers33 synthesized (Scheme 5) and bio-assayed the ligand 19. This 
ligand has potent agonist activity in comparison to anatoxin-a (cf. Figure 6). 
Scheme 5 
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Reagents: (i) PhCH2NH2; (ii) Hg(OAc)2, NaOH, NaBH4; (iii) Jones oxidation; (iv) KH, 
Et3B, allyl bromide, (v) TosMic, tBuO-K+; (vi) DIBAL-H; (vii) (a) O3, Me2S; (b) 
NH2OH.HCl, HOAC; (viii) H2,-Pd(OH)2/C, HCl. 
 
In 1993, Glassco et al.34 followed the Chavdharian’s methodology32 for the synthesis of 9 
and 10 (Scheme 6). In this work the authors described an improved synthesis of the 
starting material 25 (Scheme 6). Much later (1998), Vernier et al.35 reported on the 
synthesis and biological evaluation of a series of compounds displaying the structural 
fragment 9; in particular, compound 11 (n = 1) (Figure 4) which selectively activates 
human recombinant α2β4 and α4β4 nAChRs has been shown to be active in animal 
models of Parkinson’s disease and pain.35 In 2003 using conformationally restricted 
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nicotines 15 and 16 (Figure 4) Janda et al. reported the impressive relationship between 
the conformational constraint of nicotine and its immunogenicity.36 Conformationally 
constrained ligand 20 was synthesized by Xu et al.37 in 1999 (Scheme 7).  
Scheme 6 
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Reagents: (i) (a) LDA, (b) nitroethylene; (ii) Ra Ni, H2; (iii) NaBH3CN; (iv) CH2O, NaBH3CN. 
Scheme 7 
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Reagents: (i)  HCl; (ii) NaHCO3; (iii) NaCNBH3; (iv) (a) (Boc)2O, (b) LiOH.H2O; (v) (a) 
EtOCOCl, Et3N (b) CH2N2; (vi) PhCO2Ag, Et3N, MeOH; (vii) CaCl2, NaBH4; (viii) 
N NMs
TfO
, N-methylimidazole; (ix) LiBr; (x)  (a) n-BuLi; (b) HCl. 
 
Lindstrom et al.38 also synthesized some conformationally constrained anabasines e.g. 21 
via intramolecular Heck arylation reaction (Scheme 8). These ligands comprise a 
piperidine that is nearly perpendicular to the pyridine ring. Ullrich et al.39 synthesized a 
set of novel conformationally constrained nicotines 23 and 24 (Scheme 9 and 10). The 
racemates 23 and 24 were resolved and the ability of the individual enantiomers were 
evaluated to displace [3H]-cytisine in a rat forebrain preparation and compared with (-)-
nicotine.  The compound (+)-23b showed not only high binding affinity but also  
Scheme 8 
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Reagents: (i) Ac2O; (ii) PdCl2(PPh3)2, CuI, Et3N, HCCSiMe3; (iii) TBAF; (iv) PdCl2(PPh3)2, CuI, 
Et3N; (v) H2, Pd/C, quinoline; (vi) NaHCO3; (vii) (Tf)2O, Et3N; (viii) Pd(OAc)2, (R)-BINAP, 
Et3N; (ix) H2, Pd/C; (x) KOH, H2NNH2·H2O. 
 
significant enantioselectivity over its antipode.  This observation supports the hypothesis 
that conformational restraint can lead to high affinity ligands, which are stereochemically 
discriminated by nAChR and may feature optimum locations of the active sites of the 
pharmacophore. Very recently Yang et al.40 synthesized conformationally constrained 
nicotines 17, 10 and 18 via intramolecular azomethine ylide-alkene [3+2]-cycloaddition 
reaction which is shown in Schemes 11& 12. 
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Reagents: (i) (a) Zn, LiCl, Cu; (b) 3-bromopyridine, ClCOOEt; (c) sulfur; (ii) N-vinylpyrrolidone, 
NaH; (iii) (a) 6 N HCl; (b) Na2CO3; (iv) n-BuLi; (v) HCHO, NaBH3CN. 
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Scheme 10 
 
 
 
O
O
O N
OMe
N
Br
O OMe
OMe
N
OMe
O
O N
OMe
N
NH
OMe
H
N
N
H
N
OMe
O N
O N
OMe
I
( )n
( )n ( )n
( )n
( )n
( )n ( )n
( )n
( )n
n = 1, 2
i ii iii
iv vi
vii viii
v
24
 
 
 
 
 
 
 
 
Reagents: (i) HC(OMe)3, H2SO4 (cat.); (ii) pyrrolidine, NH4Cl (cat.); (iii) (a) LDA, BrCH2Cl; (b) 
NaI; (iv) (a) Zn, LiCl, Cu, (b) 3-bromopyridine, ClCOOEt; (c) sulfur; (v) n-BuLi; (vi) LDA, 
ICH2CN; (vii) Raney-cobalt; (viii) (a) 62% HBr; (b) Na2CO3, H2O. 
Scheme 11 
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Reagents: (i) NaH, MOMCl; (ii) n-BuLi, DMF; (iii) sarcosine; (iv) (a) HCl, (b) Zn, HCO2H. 
Scheme 12 
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Reagents: (i) (a) (CH2OH)2, TsOH; (b) CH2=CH-CH2-XH (X = O, S), OH¯; (ii) H2C2O4; (iii) 
sarcosine . 
1.3. Pharmacophoric Models  
In search of an understanding of the binding mode used by nicotinic ligands when 
interacting with nAChRs, different pharmacophoric elements have been proposed since 
1970 as shown in Figure 5.41, 17, 8  
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Figure 5. Proposed pharmacophoric elements in (S)-nicotine  
 
Here (N+) is a protonated nitrogen atom, (N) an electronegative atom capable of 
accepting a hydrogen bond, (L) a lipophilic site, (C) the centroid of a heteroaromatic ring 
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or a carbonyl carbon, and (D) a dummy atom representing a hydrogen bond donor atom 
in the receptor.  
 In 1970, Beers and Reich42 proposed a pharmacophore from physical models of 
semirigid agonists and antagonists which was based on the distance between the 
pharamacophoric elements, i.e.,  a protonated nitrogen atom (N+) and an electronegative 
atom capable of accepting a hydrogen bond, typically nitrogen or carbonyl oxygen (N). 
The distance between the centre of charge (N+) and the centre of the van der Waals 
surface of the pyridine nitrogen was 5.9 Å (the Beers-Reich distance).42 It has later been 
suggested that the angle between the line stretching from the charge centre (N+) to the 
van der Waals surface, and the line from the hydrogen bond acceptor (N) to (D) is about 
120°.43 In fact, X-ray analysis of the strychnine crystal structure shows that the distance 
between the charged nitrogen to the van der Waals surface of the ether oxygen is 5.9 Å.42 
Furthermore, the distance between the homologous functional groups in nicotine, 
trimethaphan, cytisine and acetylcholine (Figure 6) agrees with the proposed model. 
However, this pharmacophore was inadequate to explain some cases. For example, the 
ferruginines in the s-cis conformation fit the Beers-Reich distance, but not the angle. 
Conversely, in the s-trans conformations, these agonists fit the angle fairly well but not 
the distance.43 Additionally, two theoretical objections were raised as detailed below. 
a) Although Beers and Reich emphasize the charge centre (usually a quaternary 
nitrogen) as a focus of coulombic attraction, ab initio molecular orbital 
calculations show that the positive charge is dispersed among the attached 
methyl groups44, 45; it is not centred on the nitrogen atom.  
 106
b) Beers and Reich assumed that the hydrogen bond forms along the line defined by 
the carbonyl bond.  It may be guessed, however, that the hydrogen bond should 
be directed towards an orbital containing an unshared pair of electrons (i.e., at ± 
60° from this line and the plane of carbonyl carbon and its substituents for the 
sp2-hybridized orbitals of a carbonyl oxygen). Evidence in support of this has 
been reported. 46, 47 
 In 1986 Sheridan and co-workers refined the above model on the basis of the 
structures of the nicotinic agonists (S)-nicotine, (-)-cytisine, (-)-ferruginine methiodide, 
and (-)-muscarone48 (Figure 6). The essential modification in this pharmacophore was the  
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introduction of a point (C) or an atom, which defines a line along which the hydrogen 
bond may form. The optimal distances between the three points in the pharmacophore 
triangle were estimated to (N+-N) 4.8 ± 0.3 Å; (N+-C) 4.0 ± 0.3 Å; (N-C) 1.2 Å.48 
Comparing their results with those obtained by Beers and Reich, Sheridan and co-
workers found that their pharmacophore also suggested the Beers-Reich distance to be 
5.9 Å.  
The Sheridan pharmacophore model based on four ligands did not implicitly consider 
functional or binding data.  At the time the model was proposed, there was a paucity of 
nicotinic ligands and little understanding of multiple types of nACh receptors. 
A later model49 was derived by Manallack, Gallagher and Livingstone from (+)-
anatoxin-a, isoarecolone methiodide, arecolone methiodide, (-)-ferruginine methiodide, 
(S)-nicotine, and (R)-epibatidine, using (-)-cytisine as a template for alignment. The 
involved pharmacophoric elements were  
• the protonated nitrogen atom (N+)   
• the carbonyl carbon or pyridine ring centroid (C) 
• a dummy atom (D) representing a hydrogen bond donor in the receptor placed 3Å 
away from the hydrogen bond acceptor, and  
• a lipophilic region (L).  
The lipophilic region was located close to the 3΄, 4΄ carbon atoms of the pyrrolidine ring 
in (S)-nicotine. The pharmacophoric elements were related by the following distances: 
(N+-C) 3.94 Å, (C-D) 4.14 Å, (N+-D) 6.48 Å, (N+-L) 2.50 Å, (C-L) 4.07 Å, and (D-L) 
6.70 Å. Compared to the original suggestion by Beers and Reich, the authors found a 
Beers-Reich distance of 5.4 Å and a N+-C-D angle of 107°.49  
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In addition, recently a novel pharmacophore model was suggested by Tønder et 
al. 41, 50-52 based on the compounds shown in Figure 7. They reported that neither the inter 
nitrogen distance (N+-N) nor the distance between the cationic centre and the hydrogen 
bond donor in the receptor (N+-b) had any correlation with the affinity of the compounds 
(Figure 8).52 In contrast to this, the distances between the site points a, b, and c in  
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Figure 7* 
 
      * Structures with wavy lines mean that both the antipodes were considered in the computaional study.
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addition to the angle between the interatomic distance vectors a-b and a-c were closely 
correlated to affinity. Thus, in order for a compound to possess high affinity for the 
nAChRs, the pharmacophoric parameters were required to be: (a-b) 7.3 – 8.0 Å; (a-c) 6.5 
- 7.4 Å; (∆bac) 30.4 - 35.8°.52  
 
 
N+
O N
a b
c
a-b distance: 7.3 - 8.0 A0
a-c distance: 7.3 - 8.0 A0
     bac: 30.4- 35.8 0
 
 
 
Figure 8: The definition of a novel nicotinic pharmacophore model.52 
 a is the site point corresponding to a protonated nitrogen atom, b is the site point 
corresponding to the electronegative atom capable of forming a hydrogen bond, c is the 
centre of a heteroaromatic ring or a C=O bond. ∆bac is the angle measured between 
interatomic distance vectors a-b and a-c. The site points a and b are placed 2.9 Å from 
the corresponding atoms in the direction of the lone pair. 
 
Later Sharples et al.18 applied this model to explain the pharmacological 
properties of a series of hybrid molecules based on anatoxin-a and epibatidine i.e. UB-
165 analogues (Figure 9). The order of interaction potencies of these ligands towards 
nAChR α4β2* subtype are as follows: 26 > 27 > 30 = 31 > 32 >> 28>> 29. For deschloro 
UB-165 (27) the (a-b) distance (cf. Figure 8) and bac angle (∆bac) associated with 
Tønder pharmacophore52 for the α4β2* type nAChR are 7.35 Å and 35.4º respectively, 
which match with proposed pharmacophore at global mimimum energy conformation.  
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Figure 9 
The (a-b) distances determined for 28, range from 3.2 to 8.7 Å with the ∆bac values of 
25.6-35.8º. Obviously these values agree with the proposed model. In spite of this 
agreement this ligand 28 shows markedly reduced affinity for the α4β2* nAChRs. On the 
other hand the respective values for 29 are 10.1 Å and 25.4 º and these do not match with 
the model. This clearly explains the diminished binding affinity of 29 for α4β2* nAChR 
relative to 27 and 28. Sharples et al.18 also reported that like 27 the ligands 30-31 also 
conform to the basic pharmacophoric elements for the α4β2* nAChR because a 3΄-
pyridyl moiety is present in each of these ligands. Surprisingly, they possess nicotinic 
potencies for the α4β2* nAChR markedly different from that of 27. Thus, Tønder 
pharmacophore is inadequate to explain the pharmacological activity of such type of 
ligands and these data according to them provide opportunity to refine the 
pharmacophore for α4β2* nAChR as well as develop pharmacophore models appropriate 
to other nicotinic receptor subtypes.18 More recently, after the development of 3D-QSAR 
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analysis, researchers have drawn their attention to the three dimensional properties of 
ligands such as steric and electrostatic, hydrophobic, hydrogen bond donor and hydrogen 
bond acceptor properties. Using this approach several quantitative models have been 
derived using sets of homologous molecules53-57or structurally diverse nicotinic 
ligands.49, 52, 58, 59  
While the above mentioned models are helpful to rationalize the mode of 
interaction of ligands with the nAChR, some general remarks9 can be made regarding 
their use in drug design. For example, molecules are included for which the affinity, but 
not their functional (agonistic or antagonistic) properties have been reported in the 
literature. It has been shown how small changes in the chemical structure may shift 
activity from agonist to antagonist: for instance, compound 33 (X = Me) (Figure 10) 
stimulates cation efflux in K177 cells while 33 (X = n-Pr), which differs only for two 
carbon units, blocks it;60 compound 34 (R = 3-pyridyl) has antagonistic properties on 
IMR 32 cells expressing α3βx receptor, while 34 (R = 5-pyrimidinyl) is a partial agonist 
in the same preparation.61 Thus, it is possible that at least some of the models were  
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Figure 10 
derived from compounds with different functional properties. However, the mixing of 
agonists and antagonists may be misleading, since agonists bind the desensitized state 
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with high affinity, while competitive antagonists prefer the closed state. Since these are 
two different conformational states of the receptor, also the geometry of the binding site 
may be different. Additionally, the models have been built using binding affinities 
determined usually on rat brain. Although it is generally accepted that most of the 
nAChRs in this tissue (90%) belongs to the α4β2 type,62 many nAChR subunits are 
present that can coassemble to form multiple subtypes, and it has been shown that subunit 
composition can affect the affinity of ligands.63 To date, although novel agents have been 
identified that fit some of the models, the models themselves have not been used to 
design novel agents.17  According to  Romanelli and Gualtieri “the useful hints about how 
to design selective compounds can hardly be drawn from such models. Therefore, more 
binding and functional data on different nAChR subtypes are necessary to understand the 
structural requirements for selectivity, which, at present, is probably the most important 
goal in the field of nicotinic ligands”.9 It may also be appropriate to quote from a recent 
overview of α4β2 nAChR receptor pharmacophore models by Glennon and Dukat  “…… 
….even with 50 years of history nicotinic pharmacophore models still require extensive 
work.”17
 
2. Previous work from this laboratory 
 
A major emphasis of our research work in this laboratory has been to develop 
novel conformationally restricted analogues of nicotine which will exhibit high affinity 
and subtype selectivity for nAChRs without inducing typical nicotine-like side effects 
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(gastrointestinal and cardiovascular). In order to accomplish this goal, Sarkar et al. settled 
on the reported conformationally restricted analogues of nicotine, e.g. 35 and 36 (Fig. 11)  
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Figure 11 
 
because they provide a reasonable mimic of the two trans conformers of nicotine that is 
supported by crystal structure data.36 It may be mentioned here that for the 
monoprotonated species of nicotine in aqueous solution, there are four major 
conformations present, of which the two approximately isoenergetic trans rotamers are 
preferred over their cis counterparts by > 10:1 (Fig. 12).64 Like others36 we envisioned 
that the ability to “freeze out” the conformational dynamics of nicotine at various torsion 
angles (abcd) maintaining skew orientation of pyridine and pyrrolydine rings as in 35/36 
might help to identify conformational factors which appear to be critical for interaction  
 
 
 
 
 
 
Figure 12 
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with various nAChR subtypes.  The binding units or additional substituents which may be 
used to restrict the conformational flexibility of nicotine may themselves interact with the 
portion of binding site, either favorably or unfavorably, and in turn impart some 
selectivity for one subtype or another. 
During the past two decades (1983-2003), only one synthetic route* has been 
developed for the synthesis of the ring systems, e.g. 35 and 36 as shown in Scheme 4. 
However, this route does not appear to be viable for the synthesis of a large diversity of 
bridged nicotines and anabasines required to probe the conformation of (S)-nicotine 
which induces ion channel opening. Therefore, development of an alternative route which 
would be straightforward, high-yielding, and flexible is desirable.  Our group has 
addressed this issue and this is discussed here-in-after. 
In 1981 Gallagher and Magnus65 reported an elegant strategy for the in situ 
generation and trapping of indole-o-quinodimethanes, e.g. 38 as shown in Scheme 13. 
This work formed the basis for the synthesis of a large number of complex indole 
alkaloids by this group.66 Subsequently, this strategy was followed by van Leusen and co-
workers for the generation and trapping of pyrrole-2,3-quinodimethanes.67  
Scheme 13 
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* An alternative synthetic approach to the ring system 35 has been described (see Scheme 11) 
by Yang et al.40; however, this report appeared after completion of the work described in this 
chapter.
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Based on the pioneering work of Gallagher and Magnus,65 Sarkar et al. initiated  
work on a strategically different approach to compounds of the type 35 via generation of 
pyridine o-quinodimethane 42 through a formal imine tautomerisation of 41 and its 
intramolecular trapping; imine 41 can be made from its corresponding aldehyde 40  
(Scheme 14).68
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To investigate the feasibility of this approach, the imine 44a was synthesized 
from the dichloro-substituted aldehyde 43a (Scheme 15). The choice of chloro 
substituents flanking the pyridine nitrogen was crucial for this study: the C-2 chloro 
group was selected for enhanced cis-stereoselectivity at the ring juncture in the Diels-
Alder step, while the C-6 chloro group was chosen for stronger binding affinity of 
constrained nicotines and anabasines toward nAChRs. Unfortunately, treatment of 44a 
with methyl chloroformate in the presence of Hünig’s base and refluxing the mixture in 
xylene for an extended period65 did not give any traces of 46a. This failure was thought 
to be due to (i) the low acidity of methyl hydrogen which does not lend itself to rapid 
abstraction, (ii) recalcitrance of the pyridine nucleus to give up its aromaticity, or (iii) in 
situ generated o-quinodimethane intermediate being not sufficiently reactive to allow a 
Diels-Alder reaction to occur.  In order to overcome these problems it was considered  
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important to replace one of the hydrogens on the methyl group in the imine by a 
substituent which would not only make the methyl hydrogens more acidic (cf. 41) but 
also stabilize the o-quinodimethane intermediates (cf. 42). A phenylsulfanyl group 
appeared to fulfil these criteria; also it lends itself to easy reductive removal.  In the 
event, imine 44b was made from the readily available aldehyde 43b.  The formal imine 
tautomerisation reaction using methyl chloroformate in the presence of 
diisopropylethylamine this time gave the desired constrained nicotine 46b as a white 
crystalline solid in 44% yield.  This methodology was found to work satisfactorily for the 
synthesis of a large number of conformationally restricted nicotines as well as 
anabasines.68
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Pharmacological characterization of some of the synthesized conformationally 
constrained analogues at activating α3β4 nAChRs was also investigated by Sarkar et al.,68, 
69 and constrained nicotine  analogue 47 as well as constrained anabasine analogues 48 
and 49 were found to exhibit moderately potent nicotinic agonist activity (Figure 13). It 
can be mentioned that previous pharmacophore models emphasize on π-cation 
interaction for subtype selectivity. However, the pyrrolidinic nitrogen in 47, 48 and 49, 
cannot undergo protonation under physiological conditions as the same is bound to a 
carbomethoxy group. Thus, molecules such as 47, 48 and 49 do not relate to existing 
pharmacophore models.  Therefore, a refined nicotinic pharmacophore model needs to 
be developed to accommodate such molecules.  
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3. Present work  
The foregoing encouraging results on the synthesis and pharmacological 
evaluation of constrained nicotines and anabasines prompted us to undertake a similar 
investigation with the other nicotinic mimic, e.g. 36. In line with the previous work, our 
strategy for the new analogues is depicted in Scheme 16. It was also deemed important to 
introduce chloro- and sulfanylmethyl-substituents at the appropriate positions on the 
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pyridine ring and study their roles towards the efficiency and stereoselectivity during the 
ring-forming step. 
Scheme 16 
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4. Results and Discussion 
 
Our present investigation began with the synthesis of pyridine carboxaldehyde 58 
(Scheme 17).  Incidentally, this compound has not been reported in the literature till date.  
In this regard we have developed a new route for the preparation of ethyl 4-hydroxy-2-
methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (55) (Scheme 17). We initially 
attempted the condensation of ethyl 3-aminocrotonate (53) with diethyl malonate. 
However, this reaction failed. We then found from the literature that Kappe and 
Soliman70 used bis-2,4,6-trichlorophenylmalonate (54)71 instead of diethyl malonate for a 
similar condensation reaction (Scheme 18). When 53 was treated with bis-2,4,6-
trichlorophenylmalonate (54) in refluxing xylene 55 was produced as a grey solid in high 
yield (98%) (mp 225-228 °C)72a.  Presumably this condensation worked due to better 
leaving group ability of the trichlorophenoxy group of 54. Compound 55 is reported in 
the literature, but methodologies followed for its preparation suffer either from poor 
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yield (8%) when 53 is exposed to cyanoacetic acid in acetic anhydride as solvent 
followed by treatment with acid72a or inconvenience due to lack of availability of reagents 
(e.g. carbonsuboxide)72b, 73 (Scheme 19). Exposure of 55 to POCl3 at 80-90 °C  
Scheme 19 
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gave ethyl 4,6-dichloro-2-methyl-3-nicotinate (56) in 43 % yield (Scheme 17). 
Surprisingly, Stadlbauer et al. did not succeed to synthesize 56 from similar treatment of 
55 with POCl3 in presence of triethylamine under refluxing condition (Scheme 20).73 
Presence of molecular ion peak at m/z 234 ([M+H]+, C9H10Cl2NO2) in mass spectrometry 
and a strong absorption band at 1730 cm-1 due to the ester group in IR suggested the 
Scheme 20 
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formation of the dichloro compound 56. In 1H NMR the presence of two singlets at δ 
7.26 and 2.54 for pyridine and methyl protons, a quartet at 4.42 due to the CO2CH2CH3 
and a triplet at 1.40 for CO2CH2CH3 supports the structure. Additionally, the presence of 
9 lines in 13C NMR confirms the structure of 56. Reduction of the ester group in 56 to 
alcohol 57 was achieved by lithium aluminum hydride in presence of AlCl3 in ether.74 In 
the absence AlCl3 reductive elimination of chlorine might have given a poorer yield of 
the required product. Alcohol 57 was oxidized by PCC in CH2Cl2 to give the aldehyde 58 
as a pale yellow solid (mp 42 – 44 °C) in 87% yield. Formation of the aldehyde 58 is 
evident from spectral data. Presence of molecular ion peak at m/z 190 ([M+H]+, 
C7H6Cl2NO) in mass spectrometry and a strong absorption band at 1700 cm-1 due to the 
aldehyde carbonyl in IR reveals the formation of aldehyde 58. In 1H NMR the presence 
of three singlets at δ 10.56 for CHO, 7.33 for pyridine proton and at 2.75 for CH3 agreed 
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with the structure. In 13C NMR presence of a methine signal at δ 189.4 due to CHO, 
methyl carbon signal at 24.1 along with other 5 lines confirms the structure of 58. 
       Initial studies were made with imine 61, generated from the reaction of 58 with 3-
butenylamine, and this was heated to reflux in xylene in presence of Hünig’s base and 
methyl chloroformate. Unfortunately, no traces of required Diels-Alder adduct 62 was 
obtained (Scheme 21). This was of course not an unexpected result based on previous 
work of Dr. S. Basak from this laboratory.68  This failure led us to synthesize the  
Scheme 21 
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phenylsulfanyl substituted pyridinecarboxaldehyde 65 as follows. Benzylic bromination75 
of 56 (Scheme 22) followed by substitution of the bromide by phenylsulfanyl group and 
reduction (LiAlH4-AlCl3) gave 64. It may be mentioned here that the ester 63 was not 
obtained in a pure state. Indeed spectral data revealed that it was contaminated with 56. 
Fortunately, the pure alcohol 64 was isolated from column chromatography after 
reduction of 63 (+56) with lithium aluminum hydride in presence of AlCl3 in an overall 
yield of 34% from 56. Presence of molecular ion peak at m/z 300 ([M+H]+, C13H12Cl2NOS)  
suggested the formation of alcohol 64. In 1H NMR the presence of multiples at δ 7.55-
7.20 for SC6H5, singlets at 4.80 and 4.35 for two methylene protons agreed with the 
structure. Furthermore, presence of 11 lines in 13C NMR confirmed the structural assignment. 
Oxidation of the alcohol 64 with PCC afforded 65 as a yellow oil.  Presence of molecular  
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ion peak at m/z 298 ([M+H]+, C13H10Cl2NOS) in mass spectrum and absorption band at 
1704 cm-1  due to carbonyl group reveals the formation of aldehyde. Presence of a 
characteristic singlet at δ 10.46 due to CHO in 1H NMR and appearance of signal at 
189.0 due to CHO in 13C NMR confirms the formation of aldehyde 65. 
Scheme 22 
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Once again no Diels-Alder adduct, e.g. 67 was obtained when the imine 66 
obtained from 65, was refluxed with methyl chloroformate in presence of Hünig’s base in 
xylene for a prolonged period (Scheme 23).  
Scheme 23 
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This result was most surprising considering the fact that a similarly substituted 
imine, e.g. 44b underwent smooth formal tautomerisation followed by cycloaddition to 
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give the constrained nicotine 46b.  We wondered at this stage if acidity of the protons 
attached to the carbon carrying the phenylsulfanyl group in 66 was the issue. It was then 
decided to try the same reaction with 5-nitro substituted imines 68/ 69 (Figure 14). The 
substrate 69 was actually selected because we were apprehensive that synthesis of 68 
from the corresponding aldehyde would pose problems due to the competitive 
displacement of the chloro group(s) by the amine.  Indeed, such types of reactions are 
reported in the literature.76 For example reaction of chloro substituted ester 70 with a 
primary amine results in displacement of chloro group to give 71 as the major product 
(Scheme 24). 76 We of course realized that removal of the chloro groups might hamper 
stereoselectivity and/or biological activity of our target molecules, but further studies 
were conducted on 69 due to our eagerness to succeed at the cycloaddition step. As we 
shall see later (vide infra) stereochemistry indeed raised its ugly head. 
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For the synthesis of 81, our studies began with the known ester 75,77 prepared 
from the reaction of  3-aminocrotonate (53) with the highly active Michael acceptor 74, 
generated in situ from 73 78 (Scheme 25).  Reduction of 75 with DIBAL-H in 
dichloromethane gave the alcohol 78. Presence of molecular ion peak at m/z 169 
([M+H]+, C7H9Cl2N2O3)  reveals the formation of alcohol 78. In 1H NMR the presence of 
doublets at δ 9.23 and 8.58 for 2 pyridine protons, two singlets at 4.83 and 2.62 for 
CH2OH and CH3 protons supports the formation of alcohol. Presence of 7 lines in 13C 
NMR confirms the structure.  Oxidation of 78 with PCC at room temperature in 
dichloromethane gave the aldehyde 80 as a yellow crystalline solid (mp 64-65 °C).  The 
phenylsulfanyl substituted aldehyde 81 was also made from 75 via the bromide, 
displacement of the latter with potassium thiophenolate and reduction followed by 
oxidation. Like in the case of 63 the thiosubstituted ester 77 was not obtained in a pure  
Scheme 25 
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state. Rather it was found from the relative intensities of CH2SPh and CH3 groups in 1H 
NMR to be contaminated with ~20% of 75. At this stage it was hard to separate these two 
compounds by column chromatography and so the mixture was subjected to reduction. 
Thus, treatment of the above mixture with DIBAL-H in dichloromethane at -10 → -5 °C 
gave pure alcohol 79 in an overall yield of 47% from 75. Formation of alcohol was 
evident from spectral data.  Oxidation of 79 with PCC gave the aldehyde 81 in good 
yield. Presence of molecular ion peak at m/z 275 ([M+H]+, C13H11N2O3S) and absorption 
band at 1704 cm-1 in IR due to carbonyl group reveals the formation of aldehyde 81. In 
1H NMR the presence of two singlets at δ 10.16 for CHO and 4.66 for CH2SPh, doublets 
at 9.41 and 8.86 for 2 pyridine protons and a multiplet at 7.40-7.24 for SC6H5 protons 
supports the formation of the aldehyde. Additionally, presence of a methine carbon signal 
at δ 187.4 due to CHO in 13C NMR further confirmed the structure of 81.   
When 80 was treated with 3-butenylamine, with provision for removal of water 
by anhydrous Na2SO4 and molecular sieves (4 Å) imine 82 was formed (Scheme 26). 
Although imine 82 is quite unstable in air, it was possible to characterize it from 1H NMR 
which shows signals at δ 8.54 (bs, CH=NHC), 5.90-5.73 (m, CH = CH2) and 5.14-5.05 
(m, CH=CH2). When imine 82 was treated with methyl chloroformate in presence of 
Hünig’s base under refluxing condition it gave only traces (≤ 5%) of the tricyclic product 
83.  The structure of 83 was ascertained from 1H NMR which shows a characteristic 
signal for -CO2Me at δ 3.82 (s) along with disappearance of the vinylic protons of 82.  
LCMS of 83 is also supportive of its structure which shows [M+H]+ at m/z 278 
(C13H16N2O4) as a base peak.  In spite of this disappointing result this experiment proves 
that acidity of the methyl protons of 82 and possibly stability of the in situ generated o-
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quinodimethane intermediate provide the driving force for the ultimate reaction.  
Gratifyingly, when 81 was treated with 3-butenylamine and the resultant imine 69 heated 
with methyl chloroformate in presence of Hünig’s base, the constrained nicotine analogue 
84 was formed as an oil in about 33% yield (Scheme 26). TLC indicated it to be a single 
compound.  The structure of 84 was assigned on the basis of extensive NMR (1H and 13C 
NMR, 1D homonuclear decoupling experiments, COSY experiment) and HRMS data. 1H 
NMR of 84 shows a characteristic doublet at δ 5.38 (1H, J = 8.2 Hz) for C6-H proton  
Scheme 26 
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with the disappearance of signal for vinylic protons of 69.  The presence of the CO2Me 
group is evident from the appearance of a sharp singlet at δ 3.82.  13C-NMR of 84, 
however, shows 16 lines instead of the expected 17. This discrepancy may be due to 
either overlapping of a pair of signals or disappearance of a weak signal in the noise 
region.  The details of 1D homonuclear decoupling, COSY, mass spectra are discussed 
here-in- under. 
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1D Decoupling Experiments 
Irradiation at δ 5.38 (C6-H) changes spectral pattern only at δ 2.95. Also, 
irradiation at 2.95 results in collapse of the 2 line signals at 5.38 into a singlet and 
simplification of the spectral pattern at δ 2.15, 2.46, 1.85 which then should be due to C5-
H.  Irradiation at δ 3.46 changes the spectral pattern only at δ 2.15, whereas irradiation at 
δ 2.15 changes the spectral pattern at δ 3.46 and δ 2.95. This indicates that the signals at 
δ 3.46 are most likely due to C8-protons and signals at 2.15 is due to C9- protons. 
Irradiation at δ  2.46 changes the spectral pattern at δ 1.85 and δ 2.95 (C5-H) along with 
the simplification of the coupling pattern at δ  4.69.  In addition, irradiation at δ 1.85 
changes the spectral pattern at δ 2.95 (C5-H), δ 2.47 and simplification of the coupling 
pattern at δ 4.69. This clearly indicates that signals at δ 2.46 and δ 1.85 are due to the two 
geminal protons attached with C4 whereas signal at δ 4.69 is due to C3-H.  
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2D COSY Experiment 
The 2D COSY experiment shows the connectivity of the protons at δ 5.38 and δ 
2.95, which proves that δ 5.38 and δ 2.95 are due to C6-H and C5-H respectively. 
Similarly, connectivity is also observed for the protons C3-H (δ 4.69) with C4-Hβ (δ 2.46) 
and C4-Hα (δ 1.85). In the same way, this experiment also established the following 
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connectivities for protons: δ 3.46 (C8-H2) and δ  2.15 (C9-H2); δ  2.95 (C5-H) with δ  2.15 
(C9 -H2), δ  1.85 (C4-Hα), δ  2.46 (C4-Hβ), δ  5.38 (C6-H); δ  2.46 (C4- Hβ), δ  2.95 (C5-
H), δ  4.69 (C3-H) and δ 1.85 (C4- Hα). Thus, from COSY as well as 1D decoupling 
experiments the position of protons in the aliphatic region are assigned and the following 
connectivities for protons from COSY sequence is evidently present. 
C8-H/C9-H → C9-H/C5-H → C5-H/C4-H → C4-H/C3-H  
          ↓ 
   C5-H/C6-H  
Therefore, 2D COSY experiment supports the structure 84. 
 
ESI MS and HRMS data 
 ESI MS of 84 shows signals at m/z 408 for [M+Na]+ as base peak with the 
molecular ion peak at m/z 386  ([M+H]+, 60%). Other fragmentation peaks at m/z 339 for 
[M-NO2]+ (5%), 276 for [M-SPh]+ (22%) also support the composition of 84.  
In HRMS (ESI), the calculated m/z for C19H20N3O4S is 386.1175 agreed with the 
observed value of 386.1161. 
 
The stereochemistry of 84 was at first assigned from NOE difference experiments as 
follows. 
NOE difference experiments 
The relative stereochemistry at C5, C6 and C3 was determined from NOE-
difference experiment. Thus, irradiation at δ 5.38 (C6-H) resulted in a significant 
enhancement of the signal at δ  2.95 (C5-H, ~10%) whereas irradiation at δ 2.95 (C5- H) 
enhances the signal at δ 5.38 (C6-H, ~10%) and thereby establishes the cis 
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stereochemistry of the C6-H and C5-H junction protons. However, no NOE was observed 
at δ 4.69 for C3-H, when C5-H was irradiated. This establishes that the phenylsulfanyl 
group is cis to C5-H and C6-H.  All these experiments suggest that the stereochemistry of 
84 should be as given in Figure 15. Although the NOE difference experiments show that 
the BC ring is cis fused, the coupling constant (Jab) is quite high (Jab = 8.2 Hz). Based on 
literature reports (Figure 16) one would expect that the coupling constant in this case 
should be about 5-7 Hz for cis configuration and 10-12 Hz for trans configuration.  
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So, at this stage we were not absolutely sure about the stereochemistry of 84 and it 
needed further studies. Thus, exposure of 84 to NaIO4 in MeOH:H2O (1:1) gave the 
sulfoxide 89 and some amount of eliminated product 90 (Scheme 27). Refluxing 89 in 
dichloromethane gave 90 in acceptable yield as a yellow oil. Structure of 90 is fully 
supported from spectral data. Presence of molecular ion peak at m/z 276 ([M+H]+, 
C13H14N3O4) in mass spectrum and a strong absorption band at 1696 cm-1 in IR due to 
CO2Me group suggest the formation of product 86. In 1H NMR (CDCl3) the 
disappearance of the signals for SPh group at δ 7.24-7.56 and appearance of characteristic  
Scheme 27 
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signals at 6.73 (d, 1H, J = 10 Hz) and 6.61-6.42 (m, 1H) for the vinylic protons supports 
the formation of 90. Additionally, presence of 13 lines in 13C NMR confirms the 
formation of product 90. Here again we found that the coupling constant Jab is 8.6 Hz 
(Scheme 27) and this is not agreeable with the cis stereochemistry at the ring juncture. 
So, it may be concluded that the conformationally restricted nicotine, that is 90 is trans 
fused. Further analysis based on the original work of Gallagher and Magnus64 shows that 
the most favourable transition state of the pyridine o-quinodimethane intermediate from 
69 should be 91 (Scheme 28) and, therefore, the stereochemistry of the cycloadduct 
should be 84a.  
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5. Conclusion 
In conclusion, a synthesis of constrained nicotine analogues 84a and 90 has been 
achieved. Furthermore, the importance of electron withdrawing group on the pyridine 
ring and of the phenylsulfanyl group in the pyridine sidearm has been demonstrated as in 
the earlier work68 reported from our laboratory. Although the structure of 84a is evident 
from extensive NMR, HRMS data and transition state analysis, further investigation may 
be needed to confirm its stereochemistry via preparation of a solid derivative and X-ray 
crystal structure determination of the latter.  
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6. Experimental 
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2,4,6-Trichlorophenol 81 
To a vigorously stirred solution of phenol (9.6 g, 0.1 mol) in conc. HCl (150 ml) 
was added 30% H2O2 (40 ml) dropwise at 0 °C over a period of 30 min. Then the reaction 
mixture was heated at 60 °C for 4h during which orange solid was formed. After 
filtration, washing and drying 19.8 g (98%) of the title compound was obtained.  
 
Mp 68 C °C (lit.81 71 °C)  
 
Bis 2,4,6-trichlorophenyl malonate71 (54) 
To a mixture of malonic acid (3 g. 28.84 mmol), 2,4,6-trichlorophenol (9.11 g, 
46.14 mmol) was added POCl3 (10 ml) at 0 °C dropwise. Then the reaction mixture was 
allowed to come to room temperature and heated at 120-130 °C over a period of 6-7 h. 
The resulting black solution was poured into ice-cold water slowly and stirred for 5 min. 
during which a brown precipitate was formed. The precipitate was filtered and repeatedly 
washed with water (5 times) and then dried in oven for 5 h (keeping oven temperature 
below 80 °C) to give 8.5 g (63.6 %) of the title compound 54. 
 
MP. 138-139 °C. 
 
1H NMR (200 MHz, CDCl3) δ 7.40 (s, 4H), 4.05 (s, 2H). 
13C NMR (50 MHz, CDCl3) δ 161.4, 140.3, 132.69, 129.4, 128.7, 39.6. 
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Ethyl 4,6-dichloro-2-methylnicotinate (56) 
 
 
NH2H3C
EtO2C
CO2Et
CH3N
H
O
OH
POCl3
Cl
Cl
O
O
O
O
Cl
ClCl Cl
NCl
Cl
CH3
CO2Et
+
xylene, reflux
80-90 0C
53 54
55 56
98%
43 %
 
 
 
 
 
 
 
A stirred solution of 3-aminocrotonate (53) (1.29 g, 10 mmol) and bis-2,4,6-
trichlorophenyl malonate71 (54) (4.63 g, 10 mmol) in xylene (10 mL) was heated at reflux 
for 7-8 h. Then the reaction mixture was cooled to room temperature and kept for 
overnight during which a brown precipitate was formed. Filtration and washing with 
benzene 3-4 time to remove any 2,4,6-trichlorophenol gave 1.93 g of ethyl 4-hydroxy-2-
methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (55), mp 225-228 ºC (lit.72 232 ºC) in 
98% yield, which was used for the next step without further purification.  
To the pyridone 55 (1.9 g, 9.6 mmol) was added POCl3 (3.67 mL, 40 mmol) at 0 
ºC and then heated on an oil bath keeping bath temperature fixed at 80-90 ºC. After 70 h 
at that temperature the resulting black solution was cooled to room temperature, poured 
into 50 mL of ice-cold water and extracted with CH2Cl2 (3-4 times). The combined 
organic layer was washed with saturated aqueous NaHCO3 solution, dried over 
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anhydrous Na2SO4, concentrated and purified by column chromatography to give 980 mg 
(43%) of the title compound 56 as a yellow liquid. 
 
IR (CH2Cl2) 1730, 1552, 1275, 1224, 1147 cm.-1
 
1H NMR (200 MHz, CDCl3) δ 7.26 (s, 1H), 4.42 (q, 2H, J = 7.2 Hz), 2.54 (s, 3H), 1.40 (t, 
3H, J = 7.2 Hz). 
13C NMR (50 MHz, CDCl3) δ 165.0, 157.3, 151.0, 142.7, 128.0, 121.8, 62.2, 22.5, 13.9. 
 
HRMS (ESI) calcd for C9H10Cl2NO2 [M + H]+ m/z 234.0089 found 234.0081. 
Ethyl 2-methyl-5-nitronicotinate (75) 
 
 TsCl
H2N CH3
EtO2C
OH
O2N CHO
Na
O2N CHO
Cl
DMF DMF N CH3
CO2EtO2N
73 74
58 %
53
75
 
 
 
 
A solution of sodium nitromalonaldehyde monohydrate78 (73) (1.5 g, 11.2 mmol) 
in dry DMF (4 mL) was dried over 4-Å molecular sieves (2 g) for 2 h, filtered, and the 
sieves were washed with DMF (2 mL) under argon. Pyridine (5 mL) was added to the 
filtrate and the red solution was cooled to  –5 ˚C. A solution of p-toluenesulfonyl chloride 
(2.2 g, 11.2 mmol) in DMF (2 mL) was added dropwise, while the temperature was 
maintained below 0 ˚C.  The solution became very viscous and was warmed to room 
temperature slowly.  A solution of 3-aminocrotonate (53) (1.44 g, 11.2 mmol) in DMF (4 
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mL) was added dropwise and the resultant blood red solution was stirred for 24 h. The 
solvent was removed under reduced pressure.  The residue was dissolved in CH2Cl2, and 
washed with 5% aqueous Na2CO3 solution, dried over anhydrous Na2SO4 and 
concentrated. The crude product on purification by column chromatography followed by 
crystallization gave 1.2 g (58%) of 75 as white crystalline needles: mp 62˚C (lit.77 63- 64 
˚C).  
 
1H NMR (200 MHz, CDCl3) δ 9.37 (d, 1H, J = 2.4 Hz), 8.91 (d, 1H, J = 2.4 Hz), 4.42 (q, 
2H, J = 7.0 Hz), 2.93 (s, 3H), 1.42 (t, 3H, J = 7.0 Hz). 
13C NMR (50 MHz, CDCl3) δ 166.2, 164.2, 146.2, 142.1, 133.0, 125.8, 62.1, 25.0, 14.0. 
(2-Methyl-5-nitropyridin-3-yl)methanol (78) 
 
N CH3
CO2EtO2N
CH2Cl2 N
O2N
CH3
CH2OH
DIBAL-H
62 %
7875
 
 
 
To a stirred solution of 75  (400 mg, 1.90 mmol) in dry CH2Cl2 (40 mL) was 
added 6.12 mL of diisobutylaluminum hydride (1 M solution in toluene) dropwise 
keeping the bath temperature fixed at -10 → -5 ˚C over a period of 10 min. After 1 h the 
reaction mixture was quenched with saturated aqueous NH4Cl solution (10 mL) and 
stirred for 30 min at 0 ˚C. Then it was acidified with 10% HCl and the two layers so 
formed were separated. The aqueous layer was extracted with CH2Cl2 (twice), the 
combined organic fractions were washed with saturated aqueous NaHCO3 solution and 
dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and 
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purified by column chromatography (EtOAc:petroleum ether 30:70) to give 200 mg 
(62%) of the title compound 78 as a yellow crystalline solid: mp 165-167 ˚C. 
 
IR (KBr) 3197, 1595, 1519, 1354, 1052 cm.-1  
 
1H NMR (300MHz, CDCl3) δ 9.23 (d, 1H, J = 2.3 Hz), 8.58 (d, 1H, J = 2.3 Hz), 4.83 (s, 
2H), 2.62 (s, 3H). 
13C NMR (50MHz, CDCl3:DMSO-d6 10:1) δ 161.2, 142.2, 141.0, 136.2, 127.5, 59.0, 
21.1. 
 
MS (ESI) m/z (relative intensity) 210 ([M+CH3CN]H +, 47), 169 ([M+H]+, 100).  
{5-Nitro-2-[(phenylthio)methyl]pyridin-3-yl}methanol (79) 
 
 
 
N
CO2EtO2N
SPh
CH2Cl2 N
O2N CH2OH
SPh
N CH3
CO2Et
 
 
O2N
DIBAL-H
62 %
79 (47% from 75)
(i) NBS
(ii) PhSH, KOH
75 77
 
(a) Ethyl 5-nitro-2-[(phenylthio)methyl]nicotinate (77) 
 Step 1 : A stirred mixture of compound 75 (420 mg, 2 mmol), N-bromosuccinimide (450 
mg, 2.50 mmol), glacial acetic acid (0.12 mL), AIBN (2 mg) and carbon tetrachloride 
was illuminated with a 200 W lamp. After 6 h the reaction mixture was cooled to 0 ˚C 
and neutralized with saturated aqueous NaHCO3 solution. The organic layer was 
separated, dried over anhydrous Na2SO4 and evaporated under reduced pressure quickly. 
The ethyl 2-(bromomethyl)-5-nitronicotinate (76) so formed was found to undergo rapid 
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polymerization; so, the crude compound was subjected to next the step without any 
further purification.  
  
1H NMR (200MHz, CDCl3) δ 9.47 (d, 1H, J = 2.53 Hz), 9.02 (d, 1H, J = 2.48 Hz), 5.09 
(s, 2H), 4.50 (q, 2H, J = 7.1 Hz), 1.47 (t, 3H, J = 7.0 Hz); the 1H-NMR shows that 76 is 
contaminated somewhat with the starting material 75. 
 
Step 2 : To a solution of KOH (120 mg, 2.14 mmol) in ethanol (4 ml) was added 
thiophenol (0.2 mL, 2 mmol) and stirred for 15 min. This solution was added to a 
solution of  bromo compound 76 in ethanol (8 mL) at 0 °C dropwise over a period of 15 
min., during which the colour of the solution changes to deep red. After 1h, the red 
solution changes to orange and was allowed to attain room temperature and stirred 
overnight. Solvent was removed under reduced pressure, diluted with CH2Cl2, washed 
with water, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by column chromatography to give 600 mg of a mixture of 77 
and 75 (80:20) (from 1H NMR). 
 
1H NMR (200 MHz, CDCl3) δ 9.32 (d, 1H, J = 2.7 Hz), 8.92 (d, 1H, J = 2.6 Hz), 7.36-
7.21 (m, 5H), 4.74 (s, 2H), 4.43 (q, 2H, J = 6.9 Hz), 1.44 (t, 3H, J = 7.1 Hz). 
13C NMR (50 MHz, CDCl3) δ 165.6, 164.0, 146.0, 142.5, 134.5, 133.7, 130.9, 128.8, 
127.1, 125.9, 62.5, 39.8, 14.0. 
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(b) The above mixture underwent reduction by diisobutylaluminum hydride (6 mL, 6 
mmol) (1 M solution in toluene) under the same condition as described for 78 to give 260 
mg of the title compound 79 in 47% yield (from 75) as a white crystalline solid: mp 94-
96 °C. 
 
IR (KBr) 3443, 2316, 1583, 1516, 1354, 1042 cm.-1
 
1H NMR (200 MHz, CDCl3) δ 9.16 (d, 1H, J = 2.1 Hz), 8.64 (d, 1H, J = 2.1 Hz), 7.40-
7.22 (m, 5H), 4.86 (s, 2H), 4.36 (s, 2H), 2.06 (bs, 1H, -OH). 
13C NMR (50 MHz, CDCl3) 160.8, 143.4, 142.7, 136.0, 133.6, 131.4, 130.4, 129.1, 
127.6, 60.5, 38.6. 
 
MS (ESI) m/z (relative intensity) 277 ([M+H]+, 100), 259 ([M-H2O]H +, 62). 
 (4, 6-Dichloro-2-methylpyridin-3-yl)methanol (57) 
 
 
NCl
Cl
CH3
CO2Et
NCl
Cl
CH3
CH2OH
56
LiAlH4, AlCl3
Ether
57
81 %
 
 
 
To a suspension of LiAlH4 (50 mg, 1.42 mmol) in dry ether (10 mL) was added 
anhydrous AlCl3 (190 mg, 1.42 mmol) at once at 0 °C under argon. The mixture was 
stirred for 5 min followed by the addition of ethyl 4,6-dichloro-2-methylnicotinate (56) 
(100 mg, 0.85 mmol) in ether (5 ml) at that temperature. The resulting mixture was 
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heated at reflux for 3-4 h, cooled to 0 °C and quenched carefully with saturated aqueous 
Na2SO4. Two layers were separated and the aqueous layer was extracted with ether 3-4 
times. The combined ether layer was dried over anhydrous Na2SO4, concentrated and 
purified by column chromatography to give 70 mg of the title compound 57 in 81% yield 
as yellow oil. 
 
1H NMR (200 MHz, CDCl3) δ 7.25 (s,1H), 4.83 (s, 2H), 2.67 (s, 3H),1.97 (bs,1H, -OH). 
13C NMR (50 MHz, CDCl3) δ 160.5, 149.5, 146.2, 130.4, 122.3, 58.0, 22.2. 
{4,6-Dichloro-2-[(phenylthio)methyl]pyridin-3-yl}methanol (64) 
 
 
 
 
N
CO2Et
SPh
CH2Cl2 N
CH2OH
SPh
N CH3
CO2Et
DIBAL-H
64 (34 % from 56)
(i) NBS
(ii) PhSH, KOH
56 63
Cl
Cl
Cl
Cl
Cl
Cl
 
(a) Ethyl 4,6-dichloro-2-[(phenylthio)methyl]nicotinate (63) was prepared from ethyl 4,6-
dichloro-2-methylnicotinate (56) (240 mg, 1.02 mmol) as a mixture by the bromination 
followed by nucleophilic substitution of thiophenolate as described for 77.  
 
1H NMR (200 MHz, CDCl3) δ 7.51-7.15 (m, 6H), 4.54-4.35 (m, 2H), 4.29 (s, 2H), 1.49-
1.32 (m, 3H). 
(b) 63 was reduced by LiAlH4 in presence of AlCl3 in ether to give the title compound 64 
in 34% overall yield from 56 by following the same procedure as described for 79 as a 
yellow oil. 
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1H NMR (200 MHz, CDCl3) δ 7.55-7.20 (m, 6H), 4.80 (s, 2H), 4.35 (s, 2H), 2.20 (bs, 1H, 
-OH). 
13C NMR (50 MHz, CDCl3) δ 158.6, 149.8, 147.0, 133.6, 131.2, 129.9, 129.0, 127.5, 
123.8, 57.9, 39.1. 
 
HRMS (ESI) calcd for C13H12Cl2NOS [M + H]+ m/z 300.0017 found 300.0007. 
2-Methyl-5-nitronicotinaldehyde (80) 
 
PCC
CH2Cl2N
O2N
CH3
CH2OH
N CH3
CHOO2N
78 80
96%
 
 
 
To a stirred solution of 78 (200 mg, 1.19 mmol) in 20 ml of CH2Cl2 was added 
PCC (400 mg, 1.85 mmol) under argon and stirred for 1.5 h.  The resulting black reaction 
mixture was filtered over a short pad of silica gel and Celite (1:1) using 30% (EtOAc : 
petroleum ether) as eluent  to give 190 mg (96% yield) of the title compound 80 as a 
yellow crystalline solid: mp 64-65 ˚C. 
 
IR (KBr)  1702, 1575, 1354 cm.-1
 
1H NMR (200MHz, CDCl3) δ 10.38 (s, 1H), 9.47 (d, 1H, J = 2.6 Hz), 8.86 (d, 1H, J = 2.5 
Hz), 3.02 (s, 3H). 
13C NMR (50 MHz, CDCl3) δ 188.8, 165.9, 147.4, 142.8, 132.6, 128.9, 22.8. 
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MS (ESI) m/z (relative intensity) 185 ([M+H2O]H+, 100), 167 ([M+H]+, 93). 
  
4,6-Dichloro-2-methylnicotinaldehyde (58) 
 
NCl
Cl
CH3
CH2OH
Cl CH3
CHO
Cl
N
PCC
CH2Cl2
57 58
87%
 
 
 
Following the similar procedure as described for 80, 60 mg (87%) of the title 
compound was obtained by PCC oxidation starting from alcohol 57 (70 mg, 0.36 mmol) 
as a pale yellow solid: mp 42-44 °C. 
 
IR (CHCl3) 1700, 1510, 1390, 1110 cm.-1 
 
1H NMR (200 MHz, CDCl3) δ10.56 (s, 1H), 7.33 (s, 1H), 2.75 (s, 3H). 
13C NMR (50 MHz, CDCl3) δ 189.4, 162.6, 153.8, 149.4, 125.0, 123.2, 24.1. 
 
HRMS (ESI) calcd for C7H6Cl2NO [M + H]+ m/z 189.9826 found 189.9834. 
 
4,6-Dichloro-2-[(phenylthio)methyl]nicotinaldehyde (65) 
 
NCl
Cl
CH2OH
SPh
Cl
CHO
Cl
N
SPh
PCC
CH2Cl2
64 65
83%
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Following the similar procedure as described for 80, 25 mg (83%) of the title 
compound 65 was obtained by PCC oxidation of alcohol 64 (30 mg, 0.1 mmol) as a 
yellow oil. 
 
IR (CHCl3) 1704, 1540, 1080 cm.-1 
 
1H NMR (200 MHz, CDCl3) δ 10.46 (s, 1H), 7.40-7.20 (m, 6H), 4.54 (s, 2H). 
13C NMR (50 MHz, CDCl3) δ 189.0, 161.8, 153.8, 149.4, 134.5, 131.3, 128.8, 127.2, 
124.8, 124.3, 38.7. 
 
HRMS (ESI) calcd for C13H10Cl2NOS [M + H]+ m/z 297.9860 found 297.9854. 
5-Nitro-2-[(phenylthio)methyl]nicotinaldehyde (81) 
 
N
O2N CH2OH
SPh
N
CHOO2N
SPh
PCC
CH2Cl2
79 81
67%
 
 
 
 
was prepared by the PCC oxidation following the similar methodology as described for 
80, starting from 79 (150 mg, 0.54 mmol) in 67% yield as a bright yellow crystalline 
solid: mp 106-107 °C. 
 
IR (KBr) 1704, 1576, 1353 cm.-1 
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1H NMR (200 MHz, CDCl3) δ 10.16 (s, 1H), 9.41 (d, 1H, J = 2.4 Hz), 8.86 (d, 1H, J = 
2.5 Hz), 7.50-7.14 (m, 5H), 4.66 (s, 2H). 
13C NMR (50 MHz, CDCl3) δ 187.4, 165.1, 147.3, 143.3, 133.0, 132.9, 132.0, 129.1, 
128.0, 38.4.  
 
MS (ESI) m/z (relative intensity) 316 ([M+CH3CN]H +, 10), 293 ([M+H2O]H +, 7), 275 
([M+H]+, 100). 
But-3-enenylamine  
 
 
OH
 MsCl
OMs
 NaN3
DMF N3 Et2O
NH2CH2Cl2, Et3N
 Ph3/H2O
 
(a) To a stirred mixture of but-3-en-1-ol (6 g, 83.20 mmol), Et3N (23.19 mL, 0.16 mol) 
and dry CH2Cl2 (85 mL) was added CH3SO2Cl (9.74 mL, 0.12 mol) dropwise at 0 °C. 
The mixture was then stirred for 1h at 0 °C and 2h at room temperature. Ice-cold water 
was then poured into it. Aqueous layer was separated and extracted with CH2Cl2 three 
times. The combined organic extracts were thoroughly washed with water and brine, 
dried (Na2SO4) and concentrated under reduced pressure. The crude product was then 
purified by flash chromatography (silica gel, EtOAC-petroleum ether 50 : 50) to give 
corresponding mesylate as yellow liquid (12 g, 96 % yield).  
(b) NaN3 (15.6 g, 0.24 mol) was added to a stirred solution of mesylate (12 g, 0.08 mol) 
in dry DMF (80 mL) at room temperature. The resulting mixture was stirred at same 
temparature for 1 day. It was then diluted with ether and water was added. The aqueous 
layer was separated and extracted with ether. The combined organic extracts were 
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thoroughly washed with water, brine and dried (Na2SO4). This ethereal solution of azide 
was used as it is for the next step.  
(c) To the stirred ethereal solution of azide, Ph3P (27.27 g, 0.10 mol) was added in one 
portion at 0 °C. After 1 h at 0 °C (gas evolution) and 1 h at room temperature, water (4 
mL) was added. The resulting mixture was stirred at room temperature for 14 h. After 
that the reaction mixture was cooled to 0 °C. A solid mass separated out and 10% HCl 
was added dropwise to make the solution acidic. After that the resulting solution was 
filtered, washed with water and aqueous part was separated. Organic part was washed 
with water and the combined aqueous fractions were washed with small amount of ether 
and evaporated to dryness. The salt was suspended in ether, then cooled at 0 °C. The 
flask was equipped with a reflux condenser through which 40% aqueous KOH solution 
was added and the liberated amine was extracted with ether several times. Fresh beads of 
solid KOH were added to it and kept for 1 h. The aqueous layer was separated out, the 
upper amine layer was then separated and dried over a few beads of solid KOH until no 
further separation of aqueous layer occurred. The solution was decanted and distilled 
[long Vigreux column was used] to give but-4-enenylamine as a colourless liquid (3.2 g; 
52 % overall yield). 
 
1H NMR (200 MHz, CDCl3: CCl4 7:3) δ 5.81-5.55 (m, 1H), 5.1-4.9 (m, 2H), 2.70 (t, J = 
6.6 Hz, 2H), 2.2-2.05 (m, 2H).  
 
Methyl 8-nitro-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[2,3-f]quinoline-1-carboxyl-ate 
(83) 
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 N CH3
CHOO2N
N
N
O2N
H
H
MeO2C
N CH3
O2N
N
benzene
iPr2NEt / 
MeOCOCl
xylene, reflux 838280
< 5%
H2N
 
 
 
 
A stirred solution of aldehyde 80 (100 mg, 0.60 mmol) in benzene (5 mL) was 
treated with but-3-enylamine (90 mg, 1.25 mmol) at room temperature. After 1 h, to the 
reaction mixture was added anhydrous Na2SO4 (0.5 g) and stirred for another 2 h. The 
resulting mixture was filtered under argon, kept over molecular sieves (4-Å) for 12 h and 
then filtered. Benzene was removed under reduced pressure and the resulting imine 82 
was characterized by 1H NMR spectroscopy.   
 
1H NMR (200MHz, CDCl3) δ 9.32 (bs, 1H), 8.91 (d, 1H, J = 2.3 Hz), 8.54 (bs, 1H), 5.90-
5.73 (m, 1H), 5.14-5.05 (m, 2H), 3.92-3.61 (m, 2H), 2.82 (s, 3H), 2.50 (q, 2H). 
 
The crude imine 82 was diluted with xylene (4 mL), cooled to 0 °C, and treated 
with diisopropylethylamine (0.21 mL, 1.2 mmol) followed by methyl chloroformate (0.09 
mL, 1.2 mmol). After 40 min the reaction mixture was warmed to room temperature and 
heated to reflux for 4 h. The resulting black solution was cooled, solvent was removed 
under reduced pressure, diluted with CH2Cl2 and washed with 5% HCl (twice). The 
organic fragment was dried over anhydrous Na2SO4, concentrated and purified by 
preparative thin layer chromatography to give (5 mg, < 5%) of the title compound 83 as 
gummy liquid.      
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1H NMR (300MHz, CDCl3) δ 9.22 (d, 1H, J = 2.2 Hz), 8.85 (bs, 1H), 5.12 (bs, 1H), 3.82 
(s, 3H), 3.64-3.36 (m, 2H), 3.08-2.98 (m, 1H), 2.78-2.69 (m, 1H), 2.22-1.97 (m, 4H). 
 
LCMS m/z (relative intensity) 278 ([M+H]+, 100). 
Methyl 8-nitro-5-(phenylthio)-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[2,3-f]quinol-ine-
1-carboxylate (84)  
 
 
 
 
N
CHOO2N
SPh
NH2
N
O2N
N
SPh
N
N
O2N
H
H
MeO2C
SPh
benzene
iPr2NEt / 
MeOCOCl
xylene, reflux
846981 33%
 
was prepared from aldehyde 81 (100 mg, 0.36 mmol) by following the same 
methodology as described for 83 in 34% yield as a gummy liquid.  
 
1H NMR (200 MHz, CDCl3) δ 9.10 (d, 1H, J = 2.1 Hz), 8.56 (bs, 1H), 7.44-7.12 (m, 5H), 
5.38 (d, 1H, J = 8.2 Hz), 4.72-4.65 (m, 1H), 3.83 (s, 3H), 3.49-3.39 (m, 2H), 3.05-2.85 
(m, 2H), 2.58-2.41 (m, 1H), 2.30-2.10 (m, 2H), 1.95-1.75 (m, 1H).   
13C NMR (50 MHz, CDCl3) δ 162.0, 157.3, 143.8, 142.5, 133.6, 133.0, 132.8, 131.3, 
129.0, 128.0, 56.8, 53.0, 48.6, 46.3, 31.8, 30.3, 29.6. 
 
MS (ESI) m/z (relative intensity) 408 ([M+Na]+, 100), 386 ([M+H] +, 60), 339 ([M-
NO2]+, 5), 314 (12), 301 (5), 276 ([M-SPh]+, 22),  274 (15). 
HRMS (ESI) calcd for C19H20N3O4S [M + H]+ m/z 386.1175 found 386.1161. 
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Methyl 8-nitro-2,3,3a,9b-tetrahydro-1H-pyrrolo[2,3-f]quinoline-1-carboxylate (90) 
 
 
N
N
 
 
 
O2N
SPh
MeO2C
H
H
NaIO4
N
N
MeO2C
O
O2N
SPh
H
H
CH2Cl2
MeO2C
H
N
N
O2N
H
CH3OH : H2O
         = 1:1
908984
reflux
 
To a stirred solution of 84 (110 mg, 0.29 mmol) in 6 mL of methanol: water (1: 1) 
was added NaIO4 (130 mg g, 0.60 mmol) portionwise. After the solution was stirred for 
5-6 days at room temperature, water and CH2Cl2 were added and the aqueous layer was 
extracted with CH2Cl2. The combined organic fractions were washed with water, dried 
over Na2SO4 and concentrated under reduced pressure. The crude residue was purified by 
preparative thin layer chromatography (silica gel, ethyl acetate:petroleum ether 25 : 75) 
to give 55 as a yellow oil ( 20 mg) and sulfoxide 89 (70 mg). The sulfoxide 89 (70 mg) 
was then dissolved in CH2Cl2 (6 mL) and heated at reflux for 4 h. After concentration 
under reduced pressure, the crude product was purified by silica gel chromatography to 
give 90 (30 mg). The overall yield of 90 from 84 is 63%. Hydrochloride of 90 was made 
by passing dry HCl into the ethereal solution of 90 and was obtained as yellowish white 
solid.  It may be mentioned that hydrochloride of 90 is highly hygroscopic: mp 159-160 
˚C. 
 
IR (CH2Cl2) 1696, 1589, 1518, 1455, 1348 cm.-1
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1H NMR (200 MHz, CDCl3) δ 9.21 (bs, 1H), 8.51 (bd, 1H), 6.73 (d, 1H, J = 10.0 Hz), 
6.62-6.42 (m, 1H), 5.30 (d, 1H, J = 8.4 Hz), 3.78 (s, 3H), 3.72-3.45 (m, 1H), 3.43-3.20 
(m, 1H), 3.19-2.90 (m, 1H), 2.37-2.17 (m, 1H), 1.95-1.65 (m, 1H).  
13C NMR (50 MHz, CDCl3) δ 156.5, 155.6, 144.0, 143.0, 137.8, 132.4, 130.0, 128.1, 
57.4, 52.9, 45.4, 38.0, 31.0. 
 
1H NMR also run in C6D6; 1H NMR (200 MHz, C6D6) δ 9.02 (d, 1H, J = 2.3 Hz), 8.70 (s, 
1H), 6.51 (d, 1H, J = 9.6 Hz), 5.53-5.46 (m, 1H), 4.78 (d, 1H, J = 7.52 Hz), 3.36 (s, 3H), 
3.12-2.75 (m, 2H), 2.12-1.85 (m, 1H), 3.19-2.90 (m, 1H), 1.37-1.02 (m, 2H). 
 
MS (ESI) m/z (relative intensity) 317 ([M+CH3CN]H +, 8), 276 ([M+H]+, 100), 214 (22), 
199.0 ([M-CO2Me]+, 25), 158.0 (30). 
HRMS (ESI) calcd for C13H14N3O4  [M+H]+ m/z 276.0984; found 276.0989. 
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